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 In the presented study, we demonstrate that the interaction of group IVA cytosolic 
phospholipase A2 and ceramide-1-phosphate is crucial for production of eicosanoid synthesis in 
inflammation.   Inflammation is a critical component of many disease states including 
anaphylaxis, cancer, cardiovascular disease, rheumatoid arthritis, diabetes and asthma.  
Eicosanoids are well established mediators of inflammation, and the initial rate limiting step in 
the production of eicosanoids is the liberation of arachidonic acid (AA) from membrane 
phospholipids by a phospholipase A2 (PLA2).  The major phospholipase involved in this 
liberation of AA during the inflammatory response is group IVA cytosolic phospholipase A2 
(cPLA2α).  Previous studies from our laboratory demonstrated that the bioactive sphingolipid, 
ceramide-1-phosphate (C1P), binds cPLA2α at a three amino acid sequence, which is located in 
the cationic β-groove of the C2 domain of cPLA2α.   In this study we examined the effects of the 
xvii 
 
genetic ablation of ceramide kinase (CERK) on eicosanoid synthesis, as CERK is the only 
known enzyme to produce C1P in mammalian systems.  We utilized primary mouse fibroblasts 
(MEFs) and macrophages isolated from CERK-/- and +/+ mice.  The ceramide-1-phosphate and 
eicosanoid profiles were investigated, and both ceramide-1-phosphate and eicosanoid levels in 
CERK-/- MEFs were found to be dysregulated. This study also presents the development of a 
global eicosanoid method to analyze eicosanoids via LC-ESI-MS/MS.  Using this new analysis 
method, we demonstrated that there are significant differences in eicosanoid levels in ex vivo 
CERK-/- cells when compared to wild type counterparts, but the effect of the genetic ablation of 
CERK on eicosanoid synthesis and the serum levels of C1P was not apparent in vivo.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 General Information regarding lipids and their functions 
 There are four major classes of biomolecules that compose cells – proteins, 
carbohydrates, nucleic acids, and lipids.  Despite being a major class of biomolecules and 
increasing amounts of research into bioactive lipids, the important roles of lipids can also be 
overlooked.   
 Lipids are widely defined as water-insoluble organic compounds found in biological 
systems.  They typically have high solubility in nonpolar solvents and are either hydrophobic or 
amphipathic.  This broad definition of lipids includes fats, oils, waxes, some vitamins, 
cholesterols, sterols, and others.  However, lipids can be more distinctly categorized based 
upon their structure and function. 
 Fatty acids are the simplest of lipids, despite their variation in the length of the 
hydrocarbon tails, the degree of unsaturation, and the positions of the double bonds in the tails.  
They have a long hydrophobic tail and a polar head and are almost always esterified in cells.  
Fatty acids are also stored in triacylglycerols, which are very hydrophobic and are the most 
abundant lipids found in mammals.   
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Figure 1-1. Structure of ceramide-1-phosphate. 
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 Glycerophospholipids are the most abundant lipids in biological membranes.  These 
molecules are amphipathic, with a polar head and long nonpolar tails.  Of the phospholipids, 
phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylinositol (PI) are 
found primarily in the inner leaflet of the membranes, while phosphatidylcholine (PC) is mainly 
found on the outer leaflet [1-4].   Typically these lipids do not switch sides of the membrane 
leaflets on their own, but a few types of enzymes, “flippases”, “floppases”, and “scramblases”, 
can catalyze this movement [5].   
 Sphingolipids are the next most abundant lipid class found in cellular membranes.  
Ceramide is the metabolic precursor for all sphingolipids, and this class of lipids will be 
discussed in further detail in a later section.   
 Cholesterol, a member of the sterol family, is the final major component of cellular 
membranes and modulates the fluidity of membranes.  Cholesterol is also located in the blood, 
where it can be found it its free form, esterified to long chain fatty acids, and in lipoproteins.  
Lipoproteins are aggregates of lipids and proteins and enable the transport of hydrophobic lipids 
through the hydrophilic blood of the body [6].  There are five types of lipoproteins – chylomicron, 
very low density lipoprotein, intermediate density lipoprotein, low density lipoprotein, and high 
density lipoprotein [6].  In addition to cholesterol, lipoproteins have been found to transport 
phospholipids, lysophospholipids, sphingolipids, and triglycerides [7]. 
 In addition to the lipids found in cellular membranes and triglycerides, other lipids have 
important functions.  Fat-soluble vitamins A, D, E, and K are isoprenoids that are essential for 
various biological functions.  Vitamin A is important for gene expression during cell 
differentiation [8-10].  Vitamin D is essential for calcium utilization [11-12], Vitamin E is important 
for free radical reduction [13-15], and Vitamin K is required for the synthesis of proteins involved 
in blood coagulation [16].  Eicosanoids are important signaling molecules that will be discussed 
in further detail in a later section.  Cardiolipins, found in the inner mitochondrial membrane, have 
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been found to be important in the activation of enzymes – particularly those involved in oxidative 
phosphorylation [17-20]. 
 
1.2 Sphingolipids and Their Metabolism 
 Sphingolipids are a class of lipids that were first described by J.L.W. Thudichum in 1884 
[21].  The members of this family are bioactive molecules with many roles, including regulation 
of signal transduction pathways and mediation of cell-to-cell interactions [22].  Sphingolipids are 
vital to survival, as the loss of ability to synthesize them has been found to be lethal in yeast 
[23], drosophila [24], as well as in mice [25].  In humans, there are multiple diseases that occur 
when there are dysfunctions in sphingolipid metabolism.  For example, Farber disease (acid 
ceramidase deficiency), Niemann-Pick Types A&B (acid sphingomyelinase deficiency), and 
Gaucher disease (β-glucocerebrosidase deficiency) are all sphingolipid storage diseases [26]. 
 Sphingolipids are defined by their eighteen carbon amino-alcohol backbones [27] that 
include a primary hydroxyl group at C1, an amino group at C2, and a secondary hydroxyl group 
at C3, as well as a hydrophilic head group and a hydrophobic tail group (Figure 1-2).   
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Figure 1-2. The general structure of sphingolipids.  The presence of acyl chain (lower chain) 
differentiates ceramide (shown) from sphingosine.  The headgroup (R) also varies to produce 
different sphingolipids (as indicated).  Additionally, both the acyl chain and the alkyl chain vary 
in length and saturation.  Modified from Airola, et al. Handbook of Experimental Pharmacology 
2013, 215: 57-76 [28]. 
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The main classes of sphingolipids are long chain bases and their phosphates, ceramide 
and its phosphates, sphingomyelin, glucosylceramides, and galactosylceramides.  Despite the 
complexity of this class of lipids, they are all synthesized and catabolized through common 
pathways [27].  The de novo pathway of sphingolipid synthesis occurs in the endoplasmic 
reticulum (ER) where ceramide is synthesized [27].  From here, ceramide is transported 
throughout the cell to other organelles where complex sphingolipid synthesis occurs [27].    
Figure 1-3 is an overview of the metabolism of sphingolipids which will be further discussed in 
the following sections. 
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Figure 1-3. The metabolism of sphingolipids.  De novo synthesis of sphingolipids occurs in 
the ER where ceramide is formed.  From there, ceramide is transported throughout the cell and 
gives rise to all the major forms of sphingolipids in the cell. Modified from Bartke, et al. Journal 
of Lipid Research 2009, 50: 591-596 [22]. 
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1.2.1 De novo Synthesis of Ceramide 
 De novo synthesis of sphingolipids occurs in the endoplasmic reticulum (ER) through a 
chain of four reactions to generate ceramide.  The initial reaction involves the enzyme serine 
palmitoyltransferase (SPT) in the condensation of cytosolic serine and palmitoyl CoA to produce 
3-ketodihydrosphingosine [29].  The next step of the de novo pathway is the reduction of 3-
ketodihydrosphingosine by 3-Ketodihydrosphingosine Reductase (KDHR) to form 
dihydrosphingosine [27].   
The third step occurs through the acylation of dihydrosphingosine to create 
dihydroceramide [27].  In mammals, there are six distinct dihydroceramide synthases (CerS1-6) 
which are encoded by six distinct genes [30,31].  Each CerS appears to have a discrete acyl 
CoA preference; thus, each CerS produces a different dihydroceramide/ceramide species.  
Studies have shown that CerS1 prefers stearoyl CoA as a substrate and mainly produces C18-
ceramide, while CerS2 prefers C20-C26 acyl CoAs and therefore produces very long chain 
ceramides [32,33].  CerS3 prefers both middle and long chain acyl CoAs while CerS4 produces 
C18-, C20-, and C24-ceramide species [34,35]. CerS5 and CerS6 have overlapping 
preferences as they both prefer palmitoyl CoA and thus produce mainly C16-ceramide species 
[34,36].   
 The fourth and final step in de novo ceramide synthesis is the dehydration of 
dihydroceramide to ceramide [27].  The enzyme Dihydroceramide ∆4-detasurase (DES) is a 
member of the desaturase family and is responsible for this reaction [37].  There are two DES 
enzymes, DES1 and DES2, which are able to perform this action [38-40].  The action of DES1 
creates an intermediate reaction product, 4-hydroxyceramide.  This product is also known as 
phytoceramide and is the predominant ceramide species in plants and yeast [38,39].  DES2 is 
capable of producing both ceramide and phytoceramide [40]. 
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1.2.2 Ceramide Transport 
 There are two major mechanisms involved in the transport of ceramide from the ER to 
other organelles in a cell, vesicular transport and through ceramide transfer protein (CERT) [41].  
CERT is a cytosolic protein that is involved in the transport of ceramide from the ER to the Golgi 
apparatus [41].  Once ceramide has been transferred to the Golgi it can be modified into 
sphingomyelins and possibly glycosphingolipids [41].  CERT also prefers ceramide species with 
acyl chains less than C22.  It will transfer C22 and C24:1 ceramide, though the efficiency is 
reduced by approximately 60% [42,43].  However, studies have shown that CERT will not 
transfer C24 ceramide [42].  The vesicular transport of ceramide is less studied, however it is 
thought to be the major pathway responsible for delivering ceramide to the cis-Golgi for 
glycosphinoglipid synthesis [44].  
 
1.2.3 Synthesis of Complex Sphingolipids 
 There are three major groups of complex sphingolipids, and they are categorized based 
upon the primary residue attached to their C1-hydroxy headgroup.  The three major groups are: 
sphingomyelins, galactosylceramides, and glucosylceramides.   
The first complex sphingolipid, sphingomyelin, is the most abundant in mammalian cells.  
There are at least two sphingomyelin synthase (SMS) enzymes, with a possible third member of 
the family (SMSr) [45,46].  SMS enzymes produce SM by transferring a phosphocholine 
headgroup from phosphatidylcholine (PC) to ceramide.  This transfer results in the products 
diacylglycerol (DAG) and sphingomyelin (SM) [46]. 
 Galactosylceramides are synthesized by the enzyme galactosyltransferase (CGT), which 
uses UDP-galactose and ceramide.  Glucosylceramides are formed from UDP-glucose and 
ceramides by the enzyme glucosylceramide synthase (GCS) [47].    
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1.2.4 Catabolism of Sphingomyelins and Ceramides  
 The breakdown of sphingomyelin back into ceramide is an important process within 
cells.  Sphingomyelinase enzymes break down sphingolipid through the hydrolysis of the 
phosphocholine headgroups to produce ceramide and free phosphocholine [28,48]. There are 
three major categories of sphingomyelinases, and the enzymes are grouped based on their 
functionality at optimum pH – acid sphingomyelinase, alkaline sphingomyelinase, and neutral 
sphingomyelinase [28,48].  Each enzyme has different subcellular localization, and alkaline 
sphingomyelinase is only expressed in the intestine and liver.   
  As ceramides are the common precursor for all sphingolipids, they are also the common 
breakdown product.  The enzymes that are involved in the catabolism of ceramide are termed 
ceramidases.  Like the sphingomyelinases, ceramidases are also classified based upon their 
optimum pH for functionality [28]. 
 
1.2.5 Sphingosine-1-Phosphate and the Sphingosine Kinases 
 Sphingosine-1-phosphate (S1P) is a bioactive lipid that plays a role in many cellular and 
biological functions, such as migration, invasion, survival, control of immune cell trafficking, and 
angiogenesis [49-53].  S1P is produced by a sphingosine kinase which utilizes ATP to 
phosphorylate the C1 hydroxy group of sphingosine [54].  There are two sphingosine kinases 
and they have different subcellular localizations and downstream effects.  Sphingosine kinase 1 
(SphK1) is a member of the DAG kinase family and is present in the cytosol [55].  Despite the 
presence in the cytosol, SphK1 can also associate with the plasma membrane, move into the 
nucleus, and be excreted from the cell [56-60].  Sphingosine kinase 2 (SphK2) has a broader 
substrate specificity as it is able to phosphorylate phytosphingosine in addition to sphingosine 
and dihydrosphingosine [27].  SphK2 is predominantly localized in the nucleus or perinuclear 
region of cells [27].   
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1.2.6 The Salvage Pathway 
 Sphingosine, the product of sphingolipid metabolism, can be recycled through the 
“salvage pathway” where it is salvaged through reacylation and subsequent generation of 
ceramide and its derivatives [61].  Degradation of sphingolipids typically occurs in the acidic 
subcellular compartments where ceramide can be hydrolyzed to form sphingosine and free fatty 
acids [62].  From there, both products are free to leave the lysosome and re-enter the synthetic 
pathway.  This pathway has been estimated to contribute from 50% to 90% of sphingolipid 
synthesis [63,64].   
 
1.3 Ceramide Kinase and Ceramide-1-phosphate 
 Ceramide kinase (CERK) is the enzyme that phosphorylates ceramide at the first 
position to produce ceramide-1-phosphate (C1P), utilizing ATP as the phosphate donor.  In 
mammalian cells, CERK is the only known enzyme to produce C1P [65-67]. CERK mRNA has 
been reported to be highly expressed in the lymph node, spleen, and thymus [68].  CERK 
protein has been found to be expressed with moderate to high levels in the thymus, peripheral 
blood leukocytes, brain, heart, skeletal muscle, kidney, liver, and small intestine [69,70].  CERK 
has been shown to be highly expressed in resting T cells and B cells, though expression was 
reduced upon activation of these cells [72].  
 
1.3.1 The CERK protein 
CERK is an approximately 60 kDa protein that was first described as a calcium-
stimulated lipid kinase that co-purified with brain synaptic vesicles [65].  CERK activity has also 
been described in both neutrophils and HL-60 cells [66,67].  CERK has the ability to convert 
ceramide to ceramide-1-phosphate (as opposed to ceramide-3-phosphate).  Membrane-
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associated ceramide kinase activity has also been demonstrated and CERK optimally functions 
at a neutral pH optimum with Ca2+ stimulation [65-67]. 
 In 2002, the cDNA sequence for CERK was cloned by Sugiura and coworkers from 
Jurkat acute T-cell leukemic cells [262], though a ceramide phosphorylating activity was first 
isolated and characterized in 1990 [72].  As CERK has homology with the catalytic domain of 
diacylglycerol kinase (DAGK), the identification of CERK led to a new subclass of enzyme in the 
DAGK family.   
Human CERK was found to be a 537 amino acid protein which is closely related in both 
structure and amino acid homology to sphingosine kinase 1 (SphK1) and 2 (SphK2) [69] (Figure 
1-4).  CERK was found to contain the five conserved domains (C1-C5) identified for SphK1 and 
2.  CERK contains additional domains which are conserved across several species (M. 
musculus, D. melanogaster, and C. elegans) [69] including a Pleckstrin Homology (PH) domain 
in its N-terminus, between residues 8 and 124 [74].  This PH-domain is known to bind the β/γ 
subunit of heterotrimeric G-proteins, phosphoinositol-4,5-bisphosphate, as well as 
phosphorylated tyrosine residues [69].  Igarashi and coworkers and Bornancin and coworkers 
have both demonstrated that the PH-domain is required for both activity of CERK in vitro as well 
as proper localization of the enzyme in cells [73-76].  However, expression of the PH-domain 
alone resulted in improper localization, which suggests the catalytic domain also contributes to 
the specificity for specific internal membranes of the cell [69].  Interestingly, there are several 
positively charged residues within an extended loop that bridges beta strands 6 and 7 [74].  
These residues were examined through mutagenesis studies and were found to contribute to 
the stabilization of the PH domain and thus, the entire CERK protein [74].   
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Figure 1-4. The structure of CERK.  Schematic representation of the domain structure and 
conserved sequences of CERK. Pleckstrin Homology (PH) domain (yellow), Diacylglycerol 
kinase (DAGK) catalytic domain (purple); SphK C1 to C5 conserved regions within CERK 
(grey), calmodulin binding region (maroon).  
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CERK also contains a calcium/calmodulin binding motif of the 1-8-14 type B spanning 
residues 422-435 [69]. Igarashi and coworkers have demonstrated that the activation of CERK 
and the formation of its product, C1P, in response to an increase intracellular concentration of 
Ca2+, were dependent on calmodulin (CaM) [77]. Specifically, they showed that the CaM 
antagonist W-7 decreased both CERK activity and intracellular C1P formation. Additionally, 
exogenously added CaM enhanced CERK activity in vitro even at low concentrations of Ca2+. 
Overall, this indicates that calmodulin functions as the calcium sensor for CERK. 
A conserved cysteinyl motif (CXXCXXC) has also been identified in CERK. It is located 
downstream of the catalytic domain, between the CC1 and CC2 subdomains [78].  Studies have 
demonstrated that this motif is required for CERK function, including export out of the nucleus, 
localization at the Golgi, as well as enzymatic activity [78,79]. 
 
1.3.2 The CERK enzyme 
 CERK also contains two conserved phosphorylation sites, a casein kinase II 
phosphorylation site at Ser340 and a cAMP-dependent phosphorylation site at Ser424 [69].  
Bornancin and coworkers also reported two phosphorylation sites in hCERK, Ser340 and Ser408.  
Through in vitro testing of alanine mutants at these sites, it does not appear that preventing 
phosphorylation has an effect on the activity or subcellular localization of CERK [80].  There are 
also many putative protein kinase C (PKC) phosphorylation sites conserved in mammals, Ser72, 
Thr118, Thr127, Ser230, Ser300, Ser340, and Ser424 [69]. To date the effect of phosphorylation at 
Ser340 and Ser408 is not well understood, nor have the kinases responsible for the 
phosphorylation of CERK been identified and examined. 
 Phosphorylation of ceramide by CERK occurs only at the first position, yielding 
ceramide-1-phosphate and not ceramide-3-phosphate [65,66,81].  In this reaction, ATP is 
utilized as the phosphate donor, and the reaction occurs optimally at a neutral pH [65,66,82].  
To elucidate the key residues involved in the activity of CERK, the structure of CERK was 
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compared to SphK1, and thus G198 was identified in human CERK.  A mutant CERK protein 
(G198D) was created, analyzed, and shown to be devoid of activity [70,83,84], indicating G198 
is a critical amino acid for the functionality of CERK.  Calcium stimulates the phosphorylation of 
ceramide and is modulated by calmodulin.  A calcium concentration in the range of 0.1 – 500 
µM is required for the reaction [69].  
Many studies have been performed to determine the substrate specificity for CERK.  The 
specificity for ceramide is stereospecific, with a preference for the D-erythro isomer [81,85].  
Additionally, CERK prefers carbon chains longer than 12 carbons; but, with the right conditions, 
short chain ceramides can also be phosphorylated [81,85].  Ceramide is provided to CERK in 
one of two ways – 1) through de novo synthesis in the ER, followed by transport to the Golgi by 
ceramide transport protein (CERT) [86-88], or 2) as a result of SMase activity at the plasma 
membrane [89-91]. 
 As there is interest in CERK as a potential drug target, several inhibitors for its activity 
have been characterized.  K1, an olefin isomer of F-12509A, was demonstrated to be a non-
competitive CERK inhibitor [92,93].  Partial inhibition of CERK and resulting C1P production was 
demonstrated at a concentration of 100 µM.  The most potent inhibitor to date, NVP-231, is 
active in the low nanomolar range, and at 100 nM, has been demonstrated to be over 80% 
effective in cell-based assays [94,95].  However, the effectiveness of this compound in vivo has 
been shown to be limited – it has poor bioavailability as well as a rapid clearance with i.v. 
administration [95]. 
 
1.3.3 Subcellular localization of CERK 
 Many studies have been performed to determine the subcellular localization of CERK.  
Initial studies were done utilizing recombinant CERK and showed that CERK is associated with 
the particulate fraction [69,73], while others have demonstrated that CERK may localize to lipid 
rafts [84] and heavy membrane fractions [87].  Ectopic expression studies utilizing COS-1, 
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HUVEC, A549, CHO, HEK293, and COS-7 cells demonstrated that CERK is enriched in three 
major compartments – the Golgi complex, the plasma membrane, and cytoplasmic vesicles 
[73,74,76].  Immunofluorescence studies utilizing endogenous CERK confirmed that CERK was 
localized to the Golgi, though the study showed trans-Golgi rather than cis-Golgi localization 
[87]. This same study also indicated that CERK is localized to endosomal/exosomal 
compartments as well as the mitochondria, while it did not show localization to the endoplasmic 
reticulum. 
 
1.3.4 The CERK knockout mouse  
 Two groups, Bornancin and colleagues [96] and Igarashi and co-workers [97] created 
CERK knockout mice to examine the effects of CERK in vivo.  Interestingly, few phenotypes 
were found in the CERK knockout mouse, contrary to expectations. 
 Graf et al found a significant reduction in the C16 C1P levels in the serum of the CERK 
knockout mouse, but C16 C1P was not fully abolished [96].  Similarly, Igarashi and co-workers 
also generated a CERK knockout mouse and demonstrated a minor effect on total C1P levels 
[97].  Neither group presented data regarding the other subspecies of C1P.  Hence, these 
reports provided evidence that there is at least one alternative pathway for the synthesis of C1P 
in addition to CERK [96].  This alternative pathway of C1P production is still unknown, and 
developmental compensation via these uncharacterized pathways is possible as the total C1P 
levels were only minorly affected [96,97].   
Graf et al. also found that the CERK-/- animals were sensitive to both antigen (Ag)-
induced and serum transfer-induced arthritis, in contrast to the cPLA2α knockout, and similar 
responses of cells derived from both wild type and knockout animals to PMA/Ionomycin 
treatment were observed [96].  These results suggest that cPLA2α pathways are fully functional 
in the CERK-/- animals.  In contrast, this same laboratory group reported that basal PGE2 
synthesis was reduced in the bronchoalveolar (BAL) fluid of CERK-/- mice [98].   The Bornancin 
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group explored other phenotypes and reported neutropenia present in the CERK knockout 
mouse due to a reduced number of neutrophils in circulation and in the spleen.  However, they 
stated that neutrophils are still able to be produced and recruited in a peritonitis model [96].  
Finally, the only other phenotype observed by Graf et al was a rise in mortality in the CERK 
knockout mouse when it was infected with S. pneumoniae [96].   
Igarashi and coworkers explored the result of knocking out CERK in both breeding and 
in various behavior and coordination tests [97].  The group found no abnormalities in regards to 
breeding (i.e. CERK knockout mice were healthy, fertile, and mice were born at a Mendelian 
ratio) [97].  They found no difference between the wild type mice and the CERK knockout mice 
in coordination, motor skills, or motor learning.  The only observed phenotype was a possible 
difference in emotional behavior based on an open field test [97]. 
 
1.4 CERK Like protein 
 With the realization that CERK is important in many inflammatory phenotypes and that 
other lipid kinases play distinct roles in many disease states, Bornancin and colleagues began a 
search for other sphingolipid kinases.  During their search, they found a complete open reading 
frame for a putative novel CERK homolog and the putative product was named ceramide kinase 
like (CERKL) [70].  It was found on human chromosome 2q32 and spanned 13 exons over 100 
kilobases. 
 CERKL cDNA was determined to be at least 3.2 kilobases via PCR of a human brain 
cDNA library.  The protein product was 532 amino acids, with a weight of approximately 60 kDa 
[70].  The protein has a kinase domain similar to that of the diacylglycerol kinase (DAGK) family, 
with 29% identity and 50% homology to CERK [70].  In contrast to CERK mRNA which is 
expressed ubiquitously, CERKL mRNA is expressed only in the brain, kidney, trachea, testis, 
and lung. Interestingly, CERKL is not found in cells of a blood vessel origin or inflammatory 
cells, though it is found in A549, HEK293, and HeLa cells [70].  Finally, Bornancin and 
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colleagues tested the activity of CERKL and found that CERKL does not phosphorylate 
ceramides, contrary to predictions [70].   
 
1.5 Group IVA cytosolic phospholipase A2 (cPLA2α) 
Phospholipases A2 are enzymes that hydrolyze cellular phospholipids to release free 
fatty acids and, as a result, form lysophospholipids.  These lipid mediators may act as either 
intracellular messengers or they may leave the cell and interact with neighboring cells [99].   
Platelets, macrophages, neutrophils, endothelial cells, vascular smooth muscle cells, 
alveolar epithelial cells, renal mesangial cells, mast cells, and keratinocytes have all been 
shown to contain cPLA2α [100-102].  Studies have also shown that the cPLA2α protein is 
expressed in the lung, spleen, brain, and kidney of the guinea pig [99] and the spleen, brain, 
lung, heart, liver, kidney, and uterus of the mouse [103,104]. 
 
1.5.1 cPLA2α gene 
cPLA2α was first characterized in platelets and macrophage cells and was cloned from a 
macrophage cDNA library [99,105,106].   These studies demonstrated that the cPLA2α cDNA 
comprised 2880 nucleotides, which include 200 nucleotides for the 5’-untranslated region and 
approximately 500 nucleotides for the 3’-untranslated region [99,105-109].  
 
1.5.2 The cPLA2α protein 
The cPLA2α cDNA encodes for a 749 amino acid protein with a molecular weight of 
approximately 85 kDa [99].  Several discrete domains have been identified in the cPLA2α 
protein (Figure 1-5) [99].  First, near the N-terminus is a 120 amino acid domain that encodes 
the Ca2+-dependent binding of cPLA2α to membranes, referred to as the C2/CaLB domain [99, 
110].  Following the C2/CaLB domain is the catalytic domain of cPLA2α [99].  This domain 
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includes essential amino acids for catalytic activity (Arg200 and Ser228) [99,111,112].  A third 
region of the cPLA2α enzyme is the flexible hinge region [110].  This region is a 33 amino acid 
span (residues 431-463) that is devoid of hydrophobic amino acids and has homology to the 
hinge region of PKC [99]. 
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Figure 1-5. The structure of cytosolic phospholipase A2 (cPLA2α).  Schematic 
representation of the domain structure and conserved sequences of cPLA2α.  
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1.5.3 The cPLA2α Enzyme 
There are several amino acid residues that have been found to be essential for catalytic 
activity of cPLA2α.  Site-directed mutagenesis studies have been performed and these studies 
demonstrated that Ser228 is required for the catalytic function of cPLA2α [111,113].  Site-directed 
mutagenesis studies were also carried out regarding this residue, and when Asp549 was mutated 
to alanine, all catalytic activity of cPLA2α was abolished.  These studies suggest that Asp549 is 
also involved in the catalytic mechanism of cPLA2α [114].  As there is a histidine requirement for 
the function of other serine esterases and lipases, the roles of all histidines in cPLA2α were 
evaluated.  However, mutagenesis of all histidines to alanines demonstrated no significant 
reduction in cPLA2α enzymatic activity.  Thus, histidines are not involved in the catalytic 
mechanism of cPLA2α [99].  Additionally, none of the cysteines in cPLA2α were shown to be 
essential for catalytic activity [99].   
In vitro systems have been utilized to demonstrate that cPLA2α become catalytically 
active with 0.3-2 µM Ca2+, concentrations that are present in the cytosol of stimulated cells 
[99,105].  However, the catalytic activity of cPLA2α is not dependent on Ca2+, as it was 
demonstrated in vitro that the addition of salt at physiologic concentrations will also induce 
enzyme activation [115].   
Regarding the cleaving activity of cPLA2α, it preferentially cleaves arachidonic acid-
containing phospholipids with the order of preference phosphatidylcholine (PC) = 
phosphatidylinositol (PI) > phosphatidylethanolamine (PE) > phosphatidic acid (PA) = 
phosphatidylserine (PS) [116]. Within PC, there is also a preference for fatty acids as follows 
arachidonic (20:4) > linolenic (18:3) > linoleic (18:2) > oleic (18:1) ≥ palmitoleic (16:1) [116].  
Among PCs containing a twenty carbon fatty acid, the order of preference for cPLA2α is 
arachidonic (20:4) > homogammalinoleic (20:3) > eicosadienoic (20:2) > eicosenoic (20:1) > 
eicosanoic (20:0).  Activity with regards to PE also increased with chains that are more 
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unsaturated and longer than arachidonic acid, with the order being arachidonic (20:4) > 
pentaenoic (20:5) > docosahexaenoic (C22:6) = 0 [117]. 
However, activation of cPLA2α in cells (translocation to membranes and induction of AA 
release) requires an extracellular stimulus, Ca2+, and the C2/CaLB domain [99,110-112].  A 
wide variety of extracellular stimuli can activate cPLA2α.  These stimuli include growth factors, 
cytokines, interferons, and UV light [99].  Calcium ionophores, such as A23187, also induce a 
large release of arachidonic acid due to the large increase of intracellular Ca2+ levels [118].   
Phosphorylation may also play a role in the regulation of cPLA2α activation, as a variety 
of extracellular stimuli cause rapid phosphorylation of cPLA2α [99]. Ser505 has been shown to be 
phosphorylated by ERK and p38 kinases, while Ser727 is phosphorylated by p38-activated 
protein kinases [119-121].   Studies have demonstrated that mutation of either of these two 
phospho-sites has a negative effect on the ability of cPLA2α to mediate release of arachidonic 
acid [121,122].  Another report indicates that the role of Ser505 phosphorylation is to increase the 
membrane penetration of the hydrophobic resides in the active site rim of cPLA2α into the 
cellular membranes by inducing a conformational change in the enzyme [123].  Ser515 is an 
additional possible phosphorylation site of cPLA2α, though this is a debated site.  Muthalif et al 
reported that CaM kinase II phosphorylates cPLA2α at Ser515 in vitro [124], though Shimizu et al 
performed mutation studies (S515A) and saw the same level of activity in this mutant cPLA2α as 
in the wild type cPLA2α [125].  It is possible that there are additional phosphorylation sites that 
have yet to be identified, and these sites may play a role in the activation of cPLA2α. 
Over the last few years, the Chalfant laboratory has demonstrated a distinct role for 
ceramide-1-phosphate in regulating cPLA2α activation via the CaLB domain [118,126-133] 
which will be discussed in another section. 
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1.5.4 Subcellular localization of cPLA2α 
The subcellular localization of cPLA2α has been examined using Immunofluorescence 
microscopy, and studies have shown that upon activation, cPLA2α translocates to the 
endoplasmic reticulum and the nuclear membrane [134,135].  An additional study has shown 
that in subconfluent endothelial cells, a portion of cPLA2α appears within the nucleus [99,136].  
 
1.5.5 The cPLA2α Knockout Mouse 
 The cPLA2α protein has been genetically ablated in mice, and multiple studies have 
been conducted to examine both the phenotypes of these mice as well as the cells obtained 
from these mice.  One of the phenotypes observed in the cPLA2α knockout mice is that there is 
a significant breeding deficiency in regards to the female mice [103,137].  The female knockout 
mice had multiple issues regarding breeding.  First, they produced smaller litters than typically 
observed [103,137].  Second, the mice did not undergo labor at term, rather they underwent 
labor approximately two days after term should have been completed, and the pups did not 
survive labor [103].  C-sections were performed, and, of the smaller litters, the majority of the 
pups survived [103,137].  Also, a progesterone receptor antagonist was administered to induce 
labor, and 75% of the pups born survived until adulthood [103].  Bonventre et al hypothesized 
that when cPLA2α knockout males are crossed with cPLA2α knockout females that pregnancy 
typically fails around the time of implantation based upon the observation of vaginal plug 
formation [137]. 
 Additionally, a study of active anaphylaxis was performed with the cPLA2α knockout 
mice [103].  Prior to challenge, there was no difference in lung resistance observed between 
wild type and knockout mice.  However, the knockout mice recovered from challenge much 
more quickly than the wild type mice.  When the lung histology was examined, folding of the 
bronchial epithelium, narrowing of the airway, and alveolar thickening were observed in lungs 
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from the wild type mice.  However, none of these observations were made when examining 
lungs from the knockout mice.  The authors also performed a methacholine challenge after the 
ovalbumin challenge.  As expected, the wild type mice showed additional sensitivity at even the 
lowest dose of methacholine, but the knockout mice only showed sensitivity at higher doses of 
methacholine.  In fact, the responses of the knockout mice were typical to mice that were not 
challenged by ovalbumin.  The authors suggest that cPLA2α is involved in antigen-induced 
bronchial hyper-reactivity [103]. 
 The response of peritoneal macrophages to agonists was also examined [103,137].  
Peritoneal macrophages were treated with A23187, Phorbol-12-Myristate-13-Acetate (PMA), or 
lipopolysaccharide (LPS).  The response to A23187 in the wild type cells was an increase in 
production of PGE2, cysteinyl leukotrienes, and PAF, whereas the macrophages derived from 
the knockout mice did not show an increase in the production of these lipids [103,137].  
Treatment with PMA produced results similar to A23187 in that there was less arachidonic acid 
released when the knockout cells were treated than when the wild type cells were treated [137].  
Treatment with LPS likewise only affected the PGE2 response in regards to the wild type cells 
while the knockout cells were unaffected [103,137]. 
 
1.6 Ceramide-1-phosphate and cPLA2α  
The Chalfant laboratory has demonstrated that C1P is a direct activator of cPLA2α and 
that C1P is required for the translocation of group IVA cPLA2α and subsequent prostaglandin 
synthesis.  Specifically, our group has shown that the product of CERK, C1P, is required for 
activation of cPLA2α via a direct interaction between C1P and the C2/CaLB domain of cPLA2α 
[118].  This link was first introduced in 2003 when CERK-derived C1P was shown to be a 
specific and potent inducer of arachidonic acid and prostanoid synthesis in response to agonists 
in various inflammatory cells [127].  Mechanistic studies examined the specificity of this 
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interaction and C1P was shown to specifically and dramatically enhance the activity of cPLA2α 
by acting as a positive allosteric activator and interacting with cPLA2α at a novel binding site 
[129].  Surface plasmon resonance (SPR) studies and mixed micelle assays were utilized to 
identify the C1P binding site – a cationic patch on the β-groove of cPLA2α (Arg57, Lys58, Arg59), 
which lies in the C2/CaLB domain.  The mechanism of activation was then examined, which 
demonstrated that C1P acts primarily by decreasing the dissociation constant of the enzyme 
and increasing its membrane residence time [126].  As phosphatidylinositol-4,5-bisphosphate 
(PI(4,5)P2) had been shown to activate cPLA2α, the mechanism of action of this lipid was also 
examined.  PI(4,5)P2 activates cPLA2α by increasing catalytic efficiency via increased 
membrane penetration [132], a distinctly different mechanism from C1P activation of the 
enzyme.  A recent study by the Chalfant laboratory demonstrated that C1P is a proximal and 
required bioactive lipid for the activation of cPLA2α for translocation to the Golgi/perinuclear 
membranes. Specifically, our laboratory showed the interaction of C1P with cPLA2α is 
necessary for the translocation of the enzyme to internal membranes and for the production of 
PGE2 in response to inflammatory agonists [118].  
 
1.7 Eicosanoids 
Eicosanoids are a class of bioactive lipids and are important in the inflammatory 
process.  There are over 100 different eicosanoids which can be subdivided to include four main 
classes – prostaglandins, prostacyclins, leukotrienes, and thromboxanes.  These different 
eicosanoids are produced through a complex set of interacting pathways involving many 
synthesis enzymes whose expression vary by cell and tissue type [138].  The mechanism of 
synthesis begins with the rate-limiting step, the formation of arachidonic acid, via the activity of 
phospholipase A2 [139].  In many cases, inflammatory cytokines (e.g. TNFα) induce the 
activation and translocation of Group IV cytosolic phospholipase A2 (cPLA2α) in a Ca2+-
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dependent or independent manner [99,140].  After this initial activation of cPLA2α and release of 
arachidonic acid (AA), various pathways utilize the AA to synthesize multiple eicosanoids, 
Figure 1-6 [138].   
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Figure 1-6. Synthesis of eicosanoids.  Schematic representation of the production of various 
eicosanoids after arachidonic acid is released from cellular phospholipids.  
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1.7.1 Prostaglandins, Prostacyclin, and Thromboxanes 
The enzymes cyclooxygenase 1 (COX-1), which is constitutively expressed, and 
cyclooxygenase 2 (COX-2) utilize the AA released by cPLA2α to begin the prostaglandin 
synthetic pathways [140,141].  Most cells are capable of synthesizing this class of lipid 
mediators.  The COX enzymes first convert AA into PGG2, which is then reduced to PGH2.  
Next, a variety of synthetic enzymes transform PGH2 into all other prostaglandins, prostacyclin, 
and thromboxanes. 
 
1.7.2 The Lipoxygenase Pathway 
In contrast, leukotrienes (LTs) are synthesized by lipoxygenase (LOX) enzymes mainly 
by mast cells and macrophages [140,141].  5-lipoxygenase (5-LO) works in coordination with 5-
lipoxygenase activating protein (FLAP) to convert AA into 5-HPETE.  5-HPETE can then be 
reduced to 5-HETE, or 5-LOX can act again and convert 5-HPETE into leukotriene A4 (LTA4).  
Next, various synthetic enzymes can convert LTA4 into LTB4 or LTC4.  LTC4 can be further acted 
upon to produce LTD4 and LTE4. 
 
1.7.3 Cytochrome P450 Pathway 
 A third subset of enzymes, those from the cytochrome P450 pathway, can be utilized to 
convert arachidonic acid into hydroxyeicosatetraenoic acids (HETEs) and epoxytrienoic acids 
(EETs).  A variety of mixed function oxidases produce various HETE isomers, while cytochrome 
P450 epoxygenases are utilized to create various EET isomers from arachidonic acid.  The 
EETs can further be modified into dihydroxyeicosatrienoic acids (DHETs) by epoxide 
hydrolases. 
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1.8 Inflammation 
 Inflammation is composed of many coordinated processes that are actively signaled by 
both specific protein and lipid molecules [142].  The first step in the immune response involves 
inflammation and is characterized by the production of proinflammatory mediators, an influx of 
innate immune cells, and tissue destruction [143].  The resolution of inflammation involves the 
production of anti-inflammatory mediators, an influx of macrophages, and tissue repair [143].  
Eicosanoids are well established mediators of both the initiation and the resolution of 
inflammation, but there is still much to learn as the roles of only some eicosanoids have been 
well studied. 
Inflammation is a critical component of many disease states including anaphylaxis, 
cancer, cardiovascular disease, obesity, rheumatoid arthritis, diabetes and asthma [144-153].  
For example, in tumor development, inflammatory responses are involved in infiltration, 
promotion, malignant conversion, invasion, and metastasis [145].  There is also increasing 
evidence that prolonged inflammation in the vascular wall results in atherosclerosis [154-157].  
Another increasing heath concern, obesity, is also characterized by an overall inflammatory 
response in the body, and may impact the ability of the body to utilize insulin effectively [158-
160].    As inflammation plays a role in multiple disease states, gaining a greater understanding 
of the mechanisms involved in this process could lead to new strategies for disease treatment 
and prevention. 
 
1.9 Asthma 
1.9.1 Definition of Asthma 
 Asthma can be defined as a complex, chronic inflammatory disorder of the airways that 
is characterized by a variety of symptoms – including airflow obstruction, airway 
hyperresponsiveness, bronchoconstriction, and airway edema [161]. In a 2007 report, the 
National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and Prevention 
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Program published guidelines for diagnosing asthma [161].  These guidelines for asthma 
diagnosis are given below in Table 1-1. 
 
Table 1-1. Key Indicators for Considering a Diagnosis of Asthma [161] 
A diagnosis of asthma, and performing spirometry, should be considered if any of these 
indicators is present: 
1. Wheezing.  High pitched whistling sounds when breathing out, especially in children.  (Lack 
of wheezing and a normal chest examination do not exclude asthma.) 
2. History of any of the following: 
Cough, worse particularly at night 
Recurrent wheeze 
Recurrent difficulty in breathing 
Recurrent chest tightness 
3. Symptoms occur or worsen in the presence of: 
Exercise  
Viral infection 
Animals with fur or hair 
House-dust mites (in mattresses, pillows, upholstered furniture, carpets) 
Mold 
Smoke (tobacco, wood) 
Pollen 
Changes in weather 
Strong emotional expression (laughing or crying hard) 
Airborne chemicals or dusts 
Menstrual cycles 
4. Symptoms occur or worsen at night, awakening the patient. 
 
 
1.9.2 Epidemiology of Asthma 
 Though rates vary widely between countries [162], asthma affects 5-16% of people 
worldwide [163]; and, in 2010, an estimated 25.7 million people were afflicted with the condition 
[164].  During the second half of the twentieth century, the incidence of asthma rose drastically; 
but since then the incidence appears to have plateaued on a worldwide level [165].  In the UK, 
the incidence rates of asthma were approximately 10% in the 1960s, but rose to approximately 
20-30% by the mid-1990s [165].  Interestingly, the levels have not increased since the mid-
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1990s in the UK [165]. However, the incidence of asthma is still on the rise in the United States.  
From 2001 to 2010, the rate of asthma in the U.S. rose from 7.3% to 8.4%, with it mainly 
affecting children, African-Americans, and the poor [164].  Fascinatingly, the income level of 
households gives a trend in the incidence of asthma.  Of people with an income lower than the 
poverty level, the incidence rate is 11.2%, while those at twice the poverty level have an 
incidence rate of 8.7%, and those with a higher income have an incidence rate of 7.3% [164].  In 
the US, asthma is the third leading cause of hospitalization of children, exceeded only by 
pneumonia and injuries [163].  
 
1.9.3 Causes of Asthma 
 Asthma is a complex process, but it appears as if the origins of the disease primarily 
occur early in life.  Interplay of two main factors – host factors (e.g. genetics) and environmental 
exposures – are involved in the expression of the disease [161].  In addition to these factors, 
exposures that occur at a critical time in the development of the immune system are also 
involved in the expression of asthma [161]. 
 Studies have shown that multiple host factors play a role in the development of asthma.  
In 2001, Busse et al described an imbalance of Th1 and Th2 cytokine profiles being involved in 
the development of asthma [166].  In this publication, the authors stated that a shift toward a 
Th2 cytokine-like profile was prevalent in those with asthma, though this shift could occur  either 
through an overexpression of Th2 or an underexpression of Th1 [166].  Secondly, it appears as 
if there is a genetic component to the disease, though studies thus far have been unable to 
determine the causes as it is a complex issue [167,168].  Interestingly, a trend in asthma 
incidence also appears to have a gender bias.  In early life, asthma is more often found in boys, 
but at puberty, the incidence of asthma shifts predominantly to women [169]. 
 Two major environmental factors play distinct roles in the development of asthma –
respiratory infections and airborne allergens.  Respiratory infections of particular viruses, 
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especially those during infancy, have been associated with the development of asthma later in 
life.  Specifically, respiratory syncytial virus (RSV) and parainfluenza virus both cause bronchitis 
that parallels childhood asthma in multiple ways [170,171].  Airborne allergens also have been 
shown to have a major effect on the development of asthma.  For example, both house dust-
mite and cockroach exposure have been linked to sensitization towards asthma [172-174].  
Tobacco smoke [175] and air pollution [176,177] have also been demonstrated to contribute to 
the development of asthma.   
 
1.9.4 Primary Mechanism of Asthma 
 Through years of research, it has become clear that asthma is not a single disease as 
was once thought.  It is now seen and treated as a syndrome that can be caused by multiple 
biological mechanisms [178].  In the general accepted biological mechanism, environmental 
and/or inflammatory stimuli are inhaled and induce the production of mediators from the cells in 
the airway epithelium.  These mediators then recruit inflammatory cells such as eosinophils, 
lymphocytes, mast cells, and phagocytes [179-182].  These inflammatory cells then infiltrate the 
lungs and release additional mediators, such as lymphokines (e.g. IL-4, IL-5), proinflammatory 
cytokines (e.g. IL-6, TNF-α), chemokines (e.g. CCL2, CXCL8), growth factors (e.g. SCF, TGF-
β), and eicosanoids (e.g. PGD2 and leukotrienes) [178].  These mediators then augment the 
inflammatory response occurring in the epithelium, and induce chronic inflammation [178].  This 
chronic inflammation may lead to structural changes, such as smooth muscle hyperplasia, blood 
vessel proliferation, bronchoconstriction, and epithelial damage [178]. 
 
1.9.5 Current Treatments for Asthma 
 Treatment of asthma involves two components – pharmacological therapy and 
environmental control.  There are many pharmacological treatments available for the treatment 
of asthma   The main long-term treatment for asthma is inhaled corticosteroids [183], as many 
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trials have demonstrated that these are better at disease management than leukotriene receptor 
agonists [184,185].  Inhaled corticosteroids block the late phase reaction to allergens, reduce 
airway hyperresponsiveness, and inhibit inflammatory cell migration [161].  Other long term 
treatments include immunomodulators, leukotriene modulators, long-acting beta agonists 
(LABAs), and methylxanthines [161].  For quick relief of asthma, anticholinergics, short-acting 
beta agonists (SABAs), and oral systemic corticosteroids may be utilized [161]. 
 
1.10 Anaphylaxis 
1.10.1 Definition of Anaphylaxis 
Anaphylaxis is a severe systemic allergic reaction that occurs quickly upon exposure to 
an allergen and requires prompt, effective treatment and subsequent follow up care.  If not 
treated rapidly, anaphylaxis can be fatal [153].  Previously two classification systems have been 
proposed, one by Mueller [1887] and one by Brown [188].  Recently, a consensus definition was 
adopted and agreed upon, and this consensus is the new World Allergy Organization (WAO) 
guidelines.  These guidelines for the clinical criteria for diagnosing anaphylaxis were published 
in 2011 (Table 1-2) [189].  
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Table 1-2.  Clinical Criteria for Diagnosing Anaphylaxis [189] 
Anaphylaxis is highly  likely when any one of the following criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (e.g. generalized urticaria, itching or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWNG: 
A) Respiratory compromise (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expiratory flow (PEF), hypoxemia) 
B) Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g. 
hypotonia [collapse], syncope, incontinence) OR 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that 
patient (minutes to several hours) 
A) Involvement  of the skin-mucosal tissue (e.g. generalized urticaria, itch-flush, swollen lips-
tongue-uvula) 
B) Respiratory compromise (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
C) Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g. 
hypotonia [collapse], syncope, incontinence) 
D) Persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting) OR 
3. Reduced blood pressure after exposure to known allergen for that patient (minutes to 
several hours) 
A) Infants and children: low systolic blood pressure (age-specific) or greater than 30% 
decrease in systolic blood pressure 
B) Adults: systolic blood pressure of less than 90 mm Hg or greater than 30% decrease from 
that person's baseline 
 
 
1.10.2 Epidemiology of Anaphylaxis 
The incidence rate of anaphylaxis is on the rise [153].  Specifically, the incidence rate 
has more than doubled – from 21 per 100,000 people in the 1980s to 49.8 per 100,000 people 
in the 1990s [189].  More recent studies in the United Kingdom and the United States have 
demonstrated a rise in the hospital admission rate for anaphylaxis.  In the UK, a seven-fold 
increase in the number of hospitalizations occurred from 1990 (5 per million people) to 2005 (36 
per million people) [190].  Similarly, from 1994 to 2005 the New York statewide hospitalization 
rate for anaphylaxis rose from 17 per million people to 42 per million people [191].  The fatality 
rate of anaphylaxis in the US is estimated at 500-1000 people per year [192], in the UK is 
estimated at 0.33 per million people per year [193,194], and in Australia is estimated at 0.64 per 
million per year [195,196].   
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Additionally, the severity of anaphylaxis is increased in elderly patients.  In a postmortem 
analysis by Greenberger et al, the authors found that elderly patients, particularly those with 
comorbid conditions such as cardiovascular disease, comprised a significant number of the 
fatalities due to anaphylaxis [198].  Results from additional studies performed in Australia 
indicate that older age is associated with a more severe grade of anaphylaxis [196,199]. A 
report performed in Central Europe corroborated these findings demonstrating an increasing 
risk of developing circulatory symptoms in addition to cutaneous symptoms with an increase in 
age [200].   
A report by Nguyen et al. provided a possible link as to the cause of this increase in 
incidence with age.  Utilizing a mouse model, the authors demonstrated that IgE/Ag-mediated 
mast cell degranulation and edema formation increased with the age of the mice as well as 
evidence that PGE2, the bioactive lipid, becomes a mast cell stimulator with increasing age 
[201].  Despite years of study of anaphylaxis, there are still pieces of the mechanism that are 
not fully characterized.  As incidence of anaphylaxis is on the rise particularly in the elderly, 
further characterization of the mechanism is necessary to develop additional therapeutics for the 
aging population. 
 
1.10.3 Causes of Anaphylaxis  
 There are multiple causes of anaphylaxis – food, medications, and insect stings are the 
most common causative agents [197].  A 2009 study conducted in the United states indicated 
that the causes of all reported anaphylaxis cases were classified as follows: food (29.6%), 
unknown (29.6%), medications (22.2%), insects (11.1%), and other (7.4%) [202]. Additionally, 
both cold weather and exercise are able to induce anaphylaxis [203-205].  Interestingly, children 
and adults appear to have different most common inducers of anaphylaxis – children most 
commonly suffer from food-induced anaphylaxis [206] while adults more commonly suffer from 
medication-induced anaphylaxis [198]. 
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 As anaphylaxis is not always fatal, there are specific risk factors that increase the 
likelihood that an anaphylaxis event will be fatal.  Primarily, a prior anaphylactic event is a 
strong indicator that another even will follow, though it may not be life-threatening.  Co-
existence of an atopic disease greatly increases anaphylactic risk – especially asthma.  Multiple 
studies have indicated that asthma is a comorbid condition in at least 90% of fatal cases 
[196,207,193,208-210].  Cardiovascular disease is also present in a significant number of 
anaphylaxis cases [196,198].  Most interestingly, however, is that the older a person is when 
they have their first anaphylactic reaction the more likely they are to have a fatal reaction.  For 
pediatric cases, if the patient is older than 10 years of age, 54-65% of the cases are fatal 
[208,210].  For adult cases, over 75% of anaphylactic reactions to medications occur in patients 
that are between the ages of 55 and 85 years [196]. 
 
1.10.4 Primary mechanism of anaphylaxis 
The primary mechanism of anaphylaxis occurs through crosslinking of IgE and 
aggregation of FcεRI on mast cells and basophils [153].  Downstream of the initiating trigger and 
mechanism, preformed mediators (e.g. histamine) are released during degranulation of mast 
cells as well as activation of cPLA2α, and the subsequent release of AA and production of 
eicosanoids by COX and lipoxygenase enzymes [153].  Eicosanoids are bioactive lipids and 
well known inflammatory mediators that are produced as a result of mast cell activation in the 
anaphylactic response.  Primarily, cysteinyl leukotrines and prostaglandin D2 (PGD2) are 
produced in the anaphylactic response [211], and published findings from both the cPLA2α 
knockout and 5-lipoxygenase (5-LO) knockout mice have illustrated that eicosanoid pathways 
are involved in anaphylaxis.   
Uozumi and colleagues examined the cPLA2α knockout mouse in comparison to the wild 
type mouse [104].  The cPLA2α knockout mouse gave a phenotype similar to that of an 
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unchallenged mouse.  Hence, cPLA2α is involved, and thus, eicosanoids as well since activation 
and translocation of cPLA2α is required for the release of arachidonic acid from membrane 
phospholipids.  The 5-LO knockout mouse study is indicative of downstream production of 
eicosanoids as 5-LO synthesizes leukotriene A4 (LTA4), the precursor for cysteinyl leukotrienes, 
from free arachidonic acid.  When examining the 5-LO knockout mouse, Irvin et al. illustrated 
the 5-LO products are essential for the development of airway reactivity and are involved in full 
expression of Ig responses to allergens [212].  As stated above, Nguyen et al. showed that the 
eicosanoid, PGE2, becomes a mast cell stimulator with increasing age [201].  Therefore, 
eicosanoids formed from AA have distinct roles in anaphylaxis.   
 
1.10.5 Current treatments for anaphylaxis 
 The first line treatment for anaphylaxis is an intramuscular injection of epinephrine 
(adrenaline) at a dose of 0.01 mg/kg of a 1 mg/mL solution up to a maximum of 0.5 mg for 
adults and 0.3 mg for children [213-220].  Epinephrine is classified as an essential medication 
for the treatment of anaphylaxis, and it has alpha-1 adrenergic vasoconstrictor effects in most 
body organ systems [218-220].  These vasoconstrictor effects reduce mucosal edema and 
therefore prevent and relieve upper airway obstruction [218].  The vasoconstrictor effects also 
increase blood pressure (i.e. alleviates hypotension) and coronary perfusion by increasing 
peripheral vascular resistance and reversing peripheral vasodilation [218-220].  This increase in 
blood pressure occurs through the constriction of vascular beds in the precapillary resistance 
vesicles of the skin, mucosa, and kidney [273].  This ability to prevent and relieve airway 
obstruction, hypotension, and shock provide the most effective treatment for anaphylaxis [221].   
Additionally, epinephrine has β-adrenergic effects.  Stimulation of the β1-adrenergic receptors, 
the dominant receptor in the heart, leads to an increase in the rate and force of cardiac 
contractions [218].  Stimulation of the β2-adrenergic receptors, the dominant receptor in smooth 
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muscle, increases bronchodilation [218,219].  Stimulation of this receptor also increases 
intracellular cAMP levels, which then decrease the release of inflammatory mediators (e.g. 
histamine, tryptase) from mast cells and basophils [218,219].  Commonly, supplemental oxygen 
and IV saline are also given post-epinephrine treatment [221]. 
 A number of second line medications have been investigated to aid in recovery from an 
anaphylactic response.  H1-antihistamines can be used to relieve itching, flushing, urticaria, 
angioedema, and nasal and eye symptoms [222].  However, there is debate regarding how 
useful these medications are for patients.  Treatment with H2-antihistamines concurrently with 
H1-antihistamines has also been explored [223], though there is insufficient evidence with 
placebo-controlled studies to conclude that treatment is helpful.  Beta-2 adrenergic agonists 
have also been considered as additional treatment for wheezing, coughing, and shortness of 
breath [221], though they have yet to have been proven advantageous.  Glucocorticoids have 
also been evaluated [213,222,224,225], but similarly to use of the antihistamines and beta-2 
adrenergic agonists, benefits have not been proven.   
 
1.11 LC-ESI-MS/MS 
1.11.1 Liquid chromatography (LC) 
Recently, high-performance liquid chromatography (HPLC) and ultra-performance liquid 
chromatography (UPLC) have replaced thin layer chromatography (TLC) as the preferred 
method of lipid separation [226]. LC has proven to be a more versatile and more efficient 
method of separation and has the advantage of being able to be coupled to a mass 
spectrometer for further identification of lipids.  
For LC separation, two different methodologies may be utilized to separate lipids in 
different manners – normal phase and reverse phase.  In normal phase, lipids are separated 
based upon the charge of the head groups [227,228].  The head groups interact with a polar 
stationary phase, and a solvent gradient with increasing polarity will elute the lipids from the 
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column.  In contrast, reverse phase chromatography will separate lipids based upon the length 
of the acyl chains [227,229].  The acyl chains interact with an apolar stationary phase contained 
in the column and a solvent gradient with decreasing polarity will elute the lipids from the 
column.  These two methods can be utilized in tandem to further separate the lipids – first based 
upon the charged head group and then based upon the acyl chain length [230].   While 
HPLC/UPLC is an excellent tool for lipid separation, it must be paired with an additional means 
of identification to provide conclusive lipid identification and quantification information. 
 
1.11.2 Mass Spectrometry (MS) 
 Mass spectrometry provides quantitative analysis of compounds based on the mass-to-
charge ratio (m/z) of charged particles. A general summary of mass spectrometric analysis is as 
follows.  First, the sample of interest is ionized and vaporized.  Second, the ions are separated 
based on m/z by electromagnetic fields. Third, the ions are detected and processed to produce 
mass spectra that are used to provide accurate analysis. An ion source is responsible for 
vaporizing the sample, which produces ions.  These ions then proceed to the mass analyzer for 
sorting by electromagnetic fields. A detector then measures the amount of ions present to 
produce a mass spectrum [230]. 
 As previously mentioned, there are several ionization sources and mass spectrometer 
combinations commonly used for different types of analyses. One method that is commonly 
used for lipid analysis is Matrix-assisted laser desorption ionization coupled to a time-of-flight 
spectrometer (MALDI-TOF) [231]. During MALDI-TOF analysis, samples are mixed with a 
chemical matrix and dried onto a plate. A laser ionizes the sample, and the ions are introduced 
into a TOF mass spectrometer. This methodology calculates the mass for the ions based upon 
the amount of time between injection and detection, with the longer the time equaling the larger 
the ion. Although MALD-TOF provides very high sensitivity, high accuracy, and rapid sample 
analysis, matrices can often produce high background signal, making quantitative 
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measurements unreliable [232]. MALDI-TOF is therefore used primarily for qualitative analysis, 
though as technology advances this may prove to become more reliable for quantitation. 
 An additional method that is primarily utilized for qualitative information, such as 
screening for the presence of specific lipids, is shotgun lipidomics [232].  A shotgun lipidomics 
approach involves a direct injection of sample into the mass spectrometer, commonly using a 
syringe which is placed into a syringe pump to introduce the sample into the spectrometer at a 
steady rate in order to provide a steady signal [226]. While shotgun lipidomics is simple and 
quick, it may cause mass spectrometer contamination and therefore signal reduction.  As there 
is no separation prior to injection, ion suppression is a cause of concern that makes quantitative 
analysis of specific species unreliable.    
 Currently, the preferred method of lipid quantitation pairs LC separation of an extracted 
sample with analysis via tandem mass spectrometry [226].  Tandem mass spectrometry 
(MS/MS) detects compounds based upon the m/z from a precursor ion of interest and the m/z of 
its corresponding product ion.  This is obtained utilizing multiple reaction monitoring (MRM) 
mode, where a transition specific for each ion of interest is used for identification. For this 
method of quantitation, separation of an extracted samples is performed by utilizing LC after 
which the sample is introduced into the mass spectrometer (Figure 1-7).  Ionization of the 
sample is then performed by an ion source, often an electrospray source.  After ionization, the 
ions are directed to the Q0 quadrupole where a vacuum pulls the ions into the mass 
spectrometer. The Q1 quadrupole scans the ions and selects the ions of interest based upon 
the m/z of the precursor ions of interest.  These precursor ions are then sent into the Q2 
collision cell where they are fragmented to produce product ions.  These product ions are then 
sent to Q3 where the product ions of interest are selected and sent to the detector.  The 
detector generates a spectrum which is then used for analysis.  The use of the precursor to 
product ion transition paired with the retention time from the HPLC separation provides an 
accurate and sensitive method for quantitation of lipids. 
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Figure 1-7. Schematic representation of liquid chromatography tandem mass 
spectrometry. 
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CHAPTER 2 
DEVELOPMENT OF A GLOBAL EICOSANOID METHOD UTILIZING UPLC-ESI-MS/MS 
TECHNOLOGY 
 
2.1 Introduction 
 Eicosanoids are a class of bioactive lipids involved in the regulation of inflammation and 
are important in many disease states, including cancer, anaphylaxis, asthma, rheumatoid 
arthritis, and sepsis [145-153].  There are over 100 different eicosanoids, and the various 
eicosanoids contribute to the inflammatory response and various inflammatory phenotypes 
differently – some encourage inflammation while some resolve inflammation [233].  
Traditionally, eicosanoids have been monitored and quantitated via enzyme-linked 
immunosorbent assays (ELISAs) [118,127,130,103,137].  While ELISAs traditionally have low 
detection limits, there are distinct disadvantages to their use for eicosanoid analysis.  Primarily, 
ELISAs are not available for all eicosanoids, and each species must be evaluated one at a time.  
This can be costly both in time and money, as the commercially available kits are expensive.  
Using LC-ESI-MS/MS produces a distinct advantage in this area – it allows for examination of 
multiple eicosanoids in a single run as well as being able to include as many of the eicosanoids 
as desired, since a relying on a commercially available kit is not required.  LC-ESI-MS/MS also 
provides verifiable specificity utilizing a direct, rather than indirect, detection method.   
Blaho et al. published an initial protocol for analysis of multiple eicosanoids via HPLC-
ESI-MS/MS [143].  Although the Blaho method can monitor an extensive amount of eicosanoids 
(104), there are additional eicosanoids not included in their method that may be crucial to 
advancing eicosanoid research.  Additionally, both HPLC and mass spectrometry technology 
have advanced greatly since the initial method was published.  As the technology improves, it 
will be possible to analyze more eicosanoids and with a greater sensitivity than previously 
published.   
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For our new global eicosanoid method, we utilized improved chromatography technology 
through use of a Nexera UPLC system (Shimadzu), improved mass spectrometry technology 
through use of the 5500 QTRAP® (AB Sciex), and improved column technology through use of 
the Kinetix UPLC column (Phenomenex).  These technological advancements have allowed us 
to create a method with better sensitivity, an increased number of analytes, better 
chromatographic separation, and a shorter run time.  We have successfully used this 
methodology to evaluate eicosanoids for multiple peer-reviewed publications [234-237]. 
 
2.2 Materials and Methods 
2.2.1 Cell culture 
Primary mouse embryonic fibroblasts (MEFs) were isolated from 13 or 14 days pregnant 
mice, as previously described [238], and maintained for three or less passages in high glucose 
Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 20% fetal bovine serum 
(Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at 5% CO2 and at 37°C. For 
immortalized MEFs, the cells were passaged every 3 days, and after 20 serial passages of the 
primary MEFs, immortalized MEFs were obtained.   Immortalized MEFs were grown in high 
glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum (Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at 5% CO2 and at 37°C 
and passaged every 2 days.    
 
2.2.2 Baseline eicosanoid experiment 
MEFs (2 × 106) were plated in 10-cm dishes in the appropriate medium and grown under 
standard incubator conditions overnight.  The next morning, the medium was removed and 
replaced with high glucose DMEM supplemented with 2% FBS for two hours.  At the end of the 
two hour time point, the medium was removed, and fresh medium (high glucose DMEM, 0.5% 
FBS supplement) was added to the cells.  The cells were then incubated for an additional four 
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hours.  At the end of the four hour treatment, the medium was collected and the cells were 
harvested for analysis.   
 
2.2.3 Mass spectrometric analysis 
MEFs (2 × 106) were plated on 10-cm plates in the appropriate medium and grown under 
standard incubator conditions overnight. The next day cells were subjected to the relevant 
treatment.  After treatment, the plates were placed on ice, and the medium and cells were 
collected for eicosanoid analysis.   
Eicosanoids were extracted from the collected medium using a solid phase extraction 
method and analyzed as described by Blaho et al. [143] with slight modifications as reported by 
our laboratory [237].  Briefly, to 4 mL of the medium, 100 µL of internal standard containing the 
following deuterated eicosanoids was added (100 pg/µL per eicosanoid, 10 ng total per 
eicosanoid): (d4) 6k PGF1α, (d4) PGF2α, (d4) PGE2, (d4) PGD2, (d8) 5-hydroxyeicosatetranoic acid 
(5-HETE), and (d8) Arachidonic Acid.  400 µL of 10% methanol and 20 µL of glacial acetic acid 
were also added to the samples. Strata-X SPE columns (Phenomenex) were washed with 2 mL 
methanol and then 2 mL of dH2O.  The samples were applied, and then the sample vials were 
rinsed with 2 mL of 5% MeOH, which was then applied to the columns.  The eicosanoids were 
eluted with 2 mL isopropanol.  The eluent was dried under vacuum, and the samples were 
reconstituted in 100 µL of 50:50 EtOH:dH2O for LC/MS/MS analysis. 
The reconstituted eicosanoids were analyzed via UPLC-ESI-MS/MS.  A 14 minute 
reversed-phase LC method utilizing a Kinetex C18 column (150 x 2.1mm, 2.6 µm) was used to 
separate the eicosanoids at a flow rate of 500 µl/min at 50°C.  The column was equilibrated with 
100% Solvent A (water:acetonitrile:formic acid (80:20:0.02, v/v/v)) for two minutes and then 10 
µl of sample was injected.  100% Solvent A was used for the first two minutes of elution.  
Solvent B (acetonitrile:isopropanol (80:20, v/v)) was increased in a linear gradient to 25% 
Solvent B to 3 minutes, to 30% until 6 minutes, to 55% until 6.1 minutes, to 70% until 10 
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minutes, and to 100% until 10.1 minutes.  100% Solvent B was held until 13 minutes, then was 
decreased to 0% in a linear gradient until 13 minutes, and then held until 14 minutes.  The 
eicosanoids were then analyzed using a tandem quadrupole mass spectrometer (ABI 5500 Q-
Trap®, Applied Biosystems) via multiple-reaction monitoring in negative-ion mode.  Eicosanoids 
were monitored using precursor → product multiple reaction monitoring (MRM) pairs.  The mass 
spectrometer parameters used were: Curtain Gas: 30; CAD: Medium; Ion Spray Voltage: -
4500V; Temperature: 500°C; Gas 1: 45; Gas 2: 60; Declustering Potential, Collision Energy, 
and Cell Exit Potential vary per transition.   
 
2.2.4 Statistical Analysis 
Data from experiments involving the comparison of only two groups are plotted as mean 
± standard deviation.  Significance testing was performed using a two-tailed, independent 
sample t-test to compare means with p < 0.05 being considered significant.  
 
2.3 Results 
2.3.1 MS development  
 The first steps to development of a tandem mass spectrometry method are: 1) to 
determine the precursor to product ion transition for each compound, 2) to determine the 
compound dependent parameters; and 3) to determine the source dependent parameters.   
First, to determine the precursor and product ion transition, a standard solution must be 
prepared and directly infused into the mass spectrometer.  While the standard is being infused 
via syringe pump, the tuning mode is utilized to modify parameters in order to obtain a signal for 
the precursor ion of the compound of interest.  Once the parent ion is visible, the collision 
energy (i.e. the energy that hits the precursor to break it into product ions) is increased gradually 
to determine the ideal amount of energy to break the desired precursor ion into defined product 
ions.  With the optimal collision energy, a small amount of the precursor ion will still be visible, 
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while most of the signal will be from a single product ion.  It is likely that more than one product 
ion will be produced, and at this point a decision must be made as to which ion to utilize for the 
transition in the method.  To select the product ion, both how the precursor ion breaks and what 
other transitions are utilized in the method are considered.  For example, during development of 
this method, 6-keto PGF1α produced two production ions (Figure 2-1).  For 6-keto PGF1α, the 
precursor ion is 369.3 m/z, as noted in Figure 2-1.  Two product ions were created, 245.3 m/z 
and 163.1 m/z.  245.3 m/z occurs when 6-keto PGF1α breaks so that the top chain and ring stay 
together.  163.1 m/z occurs when 6-keto PGF1α breaks as described in Figure 2-1.  This product 
ion was selected to be used for 6-keto PGF1α because it is more specific than 245.3 m/z, 245.3 
m/z is used as the product ion for another eicosanoid in the method, and this product ion was 
confirmed in the literature.    
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Figure 2-1.  Determination of precursor to product ion transition of 6-keto PGF1α.  A) 
Structure of 6-keto PGF1α. The selected product ion occurs when the molecule breaks at the 
dashed line.  B) Ion scan to determine the precursor to product ion transition of 6-keto PGF1α, 
with the precursor and product ions labeled. 
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Similarly, when determining the precursor to product ion transition for PGJ2, multiple 
product ions were created, as depicted in Figure 2-2.  For PGJ2, we chose the product ion of 
233.1 m/z.  This choice was made for multiple reasons.  First, 315.2 m/z was not chosen as it is 
a loss of water.  A loss of water is not very specific to the specific precursor ion, and for that 
reason mass spectrometrists avoid this in selection of the product ion.  271.2 m/z was not 
selected as it is selected as the product ion for a different eicosanoid in the method.   233.1 m/z 
gave a distinct fragmentation to the left of OH on bottom chain, and thus was selected as the 
product ion for PGJ2.   
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Figure 2-2. Determination of precursor to product ion transition of PGJ2.  A) Structure of 
PGJ2. The selected product ion occurs when the molecule breaks just left of the OH on the 
bottom chain.  B) Ion scan to determine the precursor to product ion transition of PGJ2, with the 
precursor and product ions labeled. 
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This methodology was used to select the precursor to product ion transitions for all the 
eicosanoids in the method.  Once the ion transitions were selected, they were compared against 
the known transitions for other published methods in the literature.  For those eicosanoids that 
already have analysis methods published, our selections were verified. 
   The next step, once the ion transition is known, is to utilize flow injection analysis to 
determine the additional mass spectrometry parameters.  To perform this task, a standard of the 
compound of interest should be dissolved in a solution similar to the mobile phase composition 
as the solvents used may have an effect on some parameters.  Compound-dependent 
parameters such as Declustering Potential (DP), Entrance Potential (EP), Collision Energy (CE), 
Collision Gas Pressure, and Collision Cell Exit Potential (CXP) may be determined through 
ramping the values of parameters and examining the resulting signal.  Additionally, source-
dependent parameters such as Nebulizer Gas (for the probe), Temperature of Nebulizer Gas, 
Curtain Gas flow rate, and Needle Current may also be optimized.  Each parameter was 
separately optimized for all eicosanoids. 
 The final parameters for all eicosanoids after optimization for mass spectrometry 
analysis can be found in Table 2-1 and Table 2-2.   
 
 
Table 2-1. Finalized General Parameters for Mass Spectrometry Analysis 
General MS Parameters: 
Curtain Gas 30 
Ion Spray Voltage -4500 
Source Temperature 500 
Gas 1 45 
Gas 2 60 
CAD Medium 
Entrance Potential -10 
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Table 2-3. Finalized Compound-Dependent Parameters for Mass Spectrometry Analysis 
Compound Precursor Ion (m/z) 
Product Ion 
(m/z) DP CE CXP 
4 HNE 155 137 -140 -24 -22 
4 HNE d3 158 140 -140 -24 -22 
PGEM 327 291 -200 -24 -22 
PGFM 329 293 -200 -24 -22 
PGDM-d4 331 295 -200 -24 -22 
tetranor-PGEM-d6 333 315 -200 -24 -22 
tetranor-PGDM-d6 333 315 -200 -24 -22 
20-carboxy RvE1 379 195 -185 -38 -20 
6-keto PGF1α 369 163 -65 -34 -26 
6-keto PGF1α d4 373 167 -65 -34 -26 
PGF3 α 351 193 -200 -32 -32 
PGF2α d9 362 302 -205 -32 -25 
8-iso PGF2α d4 357 197 -200 -24 -22 
PGE3 349 269 -200 -24 -22 
PGF2α 353 193 -200 -32 -32 
8-iso PGF2α 353 193 -200 -24 -22 
RvE3 333 115 -185 -38 -20 
RvE1 349 195 -185 -38 -20 
PGF1α 355 273 -205 -32 -32 
19-hydroxy RvE1 365 195 -185 -38 -20 
20-hydroxy RvE1 365 195 -185 -38 20 
5-iPF2α-v1-d11 364 115 -200 -24 -22 
5-iPF2α-v1 353 115 -200 -24 -22 
PGE1-d4 357 277 -200 -35 -22 
11-dihydro RvE1 351 197 -185 -38 -20 
TXB3 367 169 -185 -35 -20 
LXB4 351 221 -90 -38 -18 
TXB2 369 169 -185 -24 -20 
TXB2 d4 373 173 -185 -24 -20 
17:0 LPA 423.3 152.7 -85 -33 -14 
PGE2 351 271 -200 -24 -22 
PGE2 d9 360 280 -200 -24 -22 
PGE1 353 273 -200 -35 -22 
EXD4 495 177 -85 -24 -24 
PGD2 351 271 -200 -24 -22 
Prostaglandin E1 d4 357 233 -200 -24 -22 
PGD2 d9 360 280 -200 -24 -32 
TXB1 371 171 -185 -24 -20 
PGD1 353 273 -200 -35 -22 
Cys LTD4 495 177 -85 -24 -24 
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Compound Precursor Ion (m/z) 
Product Ion 
(m/z) DP CE CXP 
Cys LTD4 d5 500.38 177 -85 -24 -24 
RvD2 375 233 -185 -38 -20 
5(S),6 (R) Lipoxin A4 d5 356 115 -280 -16 -22 
LXA4 351 115 -90 -38 -18 
15 epi LXA4 351 115 -220 -38 -34 
20-OH LTB4 351 195 -220 -38 -34 
20-COOH LTB4 365 195 -220 -38 -34 
RvD1 375 215 -90 -38 -18 
EXE4 438 333 -80 -24 -24 
EXC4 624 272 -60 -38 -38 
Omega 22 OH PD1 375 195 -185 -38 -20 
RvD5 359 137 -185 -38 -20 
RvD6 359 257 -185 -38 -20 
Cys LTE4 438 333 -80 -24 -24 
Cys LTE4 d5 443.28 338.2 -80 -24 -24 
PGA2 333 189 -200 -24 -22 
PGB2 333 235 -200 -24 -22 
PGJ2 333 271 -200 -24 -22 
Prostaglandin A2 d4 337 227 -200 -24 -22 
Cys LTC4 624.6 272 -60 -38 -38 
Cys LTC4 d5 629.42 143 -60 -38 -38 
15-diHETE 335 201 -285 -18 -18 
MaRes1 359 250 -185 -38 -20 
PD1 359 153 -90 -38 -18 
delta 15 trans PD1 359 153 -90 -38 -18 
LTB4 335 195 -220 -38 -34 
LTB4 d4 339.23 163 -220 -38 -34 
14,15-DHET d11 348 207 -280 -16 -22 
11,12-DHET d11 348 185 -280 -16 -22 
8,9-DHET d11 348 167 -280 -16 -22 
18 HEPE 317 259 -280 -16 -22 
15 dexoy ∆ 12,14 PGJ2 d4 319 203 -200 -24 -22 
20 HETE d6 325 295 -280 -16 -22 
20 HETE 319 289 -280 -16 -22 
15 HEPE 317 219 -280 -16 -22 
12 HEPE 317 179 -280 -16 -22 
11 HEPE 317 195 -280 -16 -22 
5 HEPE 317 115 -280 -16 -22 
15 HETE 319 219 -280 -16 -22 
15 HETE d8 327 226 -280 -16 -22 
17 HDHA 343 245 -280 -16 -22 
13 HDHA 343 193 -280 -16 -22 
14 HDHA 343 205 -280 -16 -22 
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Compound Precursor Ion (m/z) 
Product Ion 
(m/z) DP CE CXP 
11 HETE 319 167 -280 -16 -22 
12 oxo ETE 317 179 -280 -16 -22 
12 HETE 319 179 -280 -16 -22 
12 (S) HETE d8 327 184 -280 -16 -22 
7 HDHA 343 141 -280 -16 -22 
5 oxo ETE 317 203 -285 -18 -18 
8 HETE 319 155 -285 -18 -18 
5 HETE d8 327 116 -285 -18 -18 
5 HETE 319 115 -285 -18 -18 
3 HDHA 353 101 -280 -16 -22 
11,12 EET 319 167 -220 -20 -18 
14,15 EET 319 219 -220 -20 -16 
EET d11 330.3 268.3 -220 -20 -18 
8,9 EET d11 330 155 -280 -16 -22 
8, 9 EET 337 127 -220 -20 -20 
5,6 EET 319 191 220 -20 -14 
DHGLA 305 261 -300 -18 -18 
DHGLA d6 311 267 -300 -18 -18 
EPA 301 257 -145 -14 -14 
EPA d5 306 362 -145 -14 -14 
DHA  327 283 -145 -14 -14 
DHA d5 332 288 -145 -14 -14 
AA 303 259 -300 -18 -18 
AA d8 311 267 -300 -18 -18 
PGE2 d4 355 275 -200 -24 -22 
PGD2 d4 355 275 -200 -24 -32 
PGF2α d4 357 197 -205 -32 -25 
 
 
2.3.2 HPLC Modifications 
 We began with the conditions given in the Blaho et al. paper [143] to assess the starting 
point for our method development.  Briefly, a reverse-phase LC column was utilized (Synergy 
C18, 2.1 x 250 mm), with a flow rate of 300 µL/min and a column temperature of 50°C.  The 
column was equilibrated in 100% Solvent A (water:acetonitrile:acetic acid (70:30:0.02, v/v/v)).  
100% Solvent A was utilized for the first minute.  Solvent B (acetonitrile:isopropyl alcohol (50:50, 
v/v)) was then increased in a linear gradient to 25% solvent B until 3 minutes, to 45% until 11 
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minutes, to 60% until 13 minutes, to 75% until 18 minutes, and to 90% until 18.5 minutes. 
Solvent B was held at 90% until 20 minutes, dropped to 0% by 21 minutes, and held until 25 
minutes [143].  This method produced decent results, though we felt that with advances in 
technology we could improve upon the separation of peaks, the total analysis time, and the 
signals for the analytes. 
 First, we decided to alter the column for the method.  We have had previous success 
with the Kinetix columns (Phenomenex), which utilize new technology over traditional C18 
columns.  The Kinetex columns employ a new core shell technology in which the particles are 
not fully porous [239].  Utilizing a non-porous particle decreases the amount of time analytes 
spend diffusing in and out of the particles, which increases both plate counts and mass transfer.  
These increases result in a decrease in band broadening for higher peak efficiency [239].  We 
hypothesized that with this technology in the column, as well as the small particle size for UPLC, 
we would be able to decrease the run time while maintaining separation and sensitivity for the 
eicosanoid method.  We examined two different sizes of the Kinetix column – 2.1 x 100 mm and 
2.1 x 150 mm, both 1.7 µm and 100 Å.  During our evaluations, we determined that the longer 
column, 2.1 x 150 mm provided better separation for our eicosanoid analytes as the smaller 
column length did not provide enough theoretical plates to adequately separate a few of the 
eicosanoids (e.g. PGE2 and PGD2). 
 Secondly, we decided to examine additional possible mobile phases in order to improve 
separation of species.  Blaho et al. utilized water:acetonitrile:acetic acid (70:30:0.02, v/v/v) for 
Solvent A and acetonitrile:isopropyl alcohol (IPA) (50:50, v/v) for Solvent B [143].  We have 
observed that formic acid typically produces better results on our system, so we substituted the 
same amount of formic acid for acetic acid in Solvent A.  We varied proportions of water and 
acetonitrile (ACN) for Solvent A (100% dH2O, 80:20 dH2O:ACN, and 60:40 dH2O:ACN) all with 
0.02% formic acid.  Adjustments were also attempted with Solvent B (50:50 ACN:IPA, 80:20 
ACN:IPA and 100% ACN) with and without 0.02% formic acid. 
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 The final components of an LC method are the flow rate and the ratio of Solvent A to 
Solvent B that is used to elute the analytes of interest from the column.  As we are using 
reverse-phase chromatography, we wanted to increase the percentage of non-polar solvent in 
the system in order to elute the analytes.  We started with the conditions in the Blaho et al. 
paper [143] and adjusted from those parameters.  A wide variety of modifications were tested to 
improve the separation of analytes (particularly PGE2 and PGD2) as well as increase the signal-
to-noise ratio and reduce peak broadening.  Multiple flow rates were examined, ranging from 
150 µL/min to 500 µL/min.  A range of initial conditions (%B) were also explored, from 0% up to 
50% B at the start of the run.  We also investigated a wide variety of gradient adjustments – 
from quick, steep gradients straight to 100% B in as little time as possible, to slow gradients 
over an extended period of time, to stepwise gradients with holds throughout the method.   
 Our finalized LC method for eicosanoid analysis utilized the Kinetix XB-C18 column (2.1 
x 150 mm, 1.7 µm, 100 Å).  Solvent A is 80:20 dH2O:ACN with 0.02% formic acid and Solvent B 
is 80:20 ACN:IPA.  The method utilizes a flow rate of 500 µL/min, a column temperature of 
50°C, and an injection volume of 10 µL.  The gradient is given in the table below (Table 2-3). 
 
Table 2-3.  Finalized gradient of the LC method. 
Time (min) Solvent B 
0.0 0% 
2.0 0% 
3.0 25% 
6.0 30% 
6.1 55% 
10.0 70% 
10.1 100% 
13.0 0% 
14.0 0% 
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2.3.3 Capability of the Method 
 Finally, capability of the method must be analyzed.  This is typically tested using 
samples of types that are desired for analysis.  For this confirmation, we utilized media samples 
from both CERK+/+ and CERK-/- MEFs.  Of the eicosanoids examined, five were detected in 
quantifiable amounts (Table 2-4).  Specifically, arachidonic acid, PGE2, PGF2α, 5-HETE, and 
11-HETE were basally produced in appreciable amounts by CERK+/+ MEFs.  Importantly, the 
production these eicosanoids were significantly reduced in CERK-/- cells with the exception of 
PGF2α, which was not statistically significantly different in the CERK-/- MEFs (Figure 2-3 and 
Table 2-4).   
 For example, the levels of both 5-HETE and 11-HETE were reduced by approximately 
50% in the media from the CERK-/- MEFs compared to CERK+/+ MEFs. Arachidonic acid and 
PGE2 demonstrated more dramatic decreases of approximately 59% and 71%, respectively.  
PGF2α presented with an insignificant increase of approximately 20% with CERK-/- MEFs 
compared to the wild type MEFs.   The ability to distinguish differences in the media obtained 
from these cells demonstrates that the newly developed method has the capability of analyzing 
biological samples. 
 
Table 2-4. Eicosanoids produced by Immortalized MEFs in 0.5% Serum. 
Eicosanoid CERK+/+           (ng/mL media) 
CERK-/-            
(ng/mL media) 
% Control 
(CERK+/+) 
Arachidonic Acid 0.68 0.28 41% 
PGE2 0.17 0.05 29% 
PGF2α 0.05 0.06 120% * 
5 HETE 0.04 0.02 50% 
11 HETE 0.11 0.06 55% 
   
* Not 
Significant 
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Figure 2-3. Genetic ablation of ceramide kinase induces a loss in the production of basal 
eicosanoids.  Immortalized MEFs (2 × 106) were plated in 10 cm dishes and incubated under 
standard conditions overnight.  The next morning, the medium was replaced with 2% serum 
medium for two hours and were then switched to 0.5% serum media and incubated for four 
hours.  Media was then collected and analyzed via HPLC-ESI MS/MS as described in the 
Materials and Methods section to evaluate the levels of (A) arachidonic acid, (B) PGE2, (C) 
PGF2α, (D) 5-HETE, and (E) 11-HETE.  Data are representative of n=6. 
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2.4 Discussion 
For this improved global eicosanoid method, we utilized advanced chromatography 
technology through use of a Nexera UPLC system (Shimadzu), improved mass spectrometry 
technology through use of the 5500 QTRAP® (AB Sciex), and advance column technology 
through use of the Kinetix UPLC column (Phenomenex).  We have successfully added multiple 
eicosanoids to the global eicosanoid method and have used this methodology to evaluate 
eicosanoids for multiple peer-reviewed publications [234-237]. 
 The technological improvements that have occurred since the initial publication of a 
method to analyze multiple eicosanoids by Blaho et al. [143] have been crucial to the ability to 
develop the current improved global eicosanoid method.  The Nexera UPLC system is designed 
to allow optimal high-throughput analysis, which is important for development of a time-saving, 
reproducible analysis of over 100 different eicosanoid species in a single run.  However, to truly 
take advantage of what this system has to offer, the mass spectrometer to which it is paired is 
crucial.  The 5500 QTRAP® provides enhanced speed and sensitivity over the 4000 QTRAP® 
model which was utilized by Blaho et al [143].  While both systems utilize the TurboVTM ion 
source, the 5500 has the QJet® ion guide with improved ion containment and better collisional 
focusing, which enhances ion transmission into the source.  The quadrupole scan speed has 
also decreased from 24,000 Da/s to 12,000 Da/s which allows maximal utilization of the 
scheduled MRM function to increase sensitivity for every analyte despite having 100+ analytes 
in the method.    In addition to UPLC and mass spectrometry improvements, UPLC column 
technology has also improved.  The Phenomenex Kinetex XB-C18 column has distinct 
advantages over a traditional C18 column in addition to the decrease in particle size that is 
common with UPLC columns.  The Kinetex columns utilize a new core shell technology in which 
the particles are not fully porous [239].  Utilizing a non porous particle decreases the amount of 
time analytes spend diffusing in and out of the particles which increases both plate counts and 
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mass transfer.  These increases result in a decrease in band broadening for higher peak 
efficiency [239].   
This method is a vast improvement over methods that are currently available for 
eicosanoid analysis.  First, this method is an improvement over ELISAs in that it provides 
verifiable specificity utilizing a direct, rather than indirect, detection method.  It also provides the 
ability to analyze all eicosanoids in a single run.  However, the distinct advantage is that this 
method allows for examination of multiple eicosanoids in a single run as well as being able to 
include as many of the eicosanoids as desired.  This method is also an improvement over the 
Blaho et al. method [143] in that the sensitivity has increased and analysis time has has 
decreased.  Utilizing the Nexera UPLC system, the 5500 QTRAP®, and the Kinetix UPLC 
column have provided increased sensitivity, a shorter run time, and better separation of analytes 
of interest.   
In the future this method will be able to continually be adapted as instrumentation 
parameters for both LC and mass spectrometry are increased.  With additional technological 
advances the time required for this analysis will decrease while sensitivity increases.  In the 
future the creation of a quick and robust method may lead to personal assessments of 
eicosanoid levels and could play a role in patient-specific treatment for a wide variety of disease 
states. 
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CHAPTER 3 
CHARACTERIZATION OF EICOSANOID SYNTHESIS IN A GENETIC ABLATION MODEL 
OF CERAMIDE KINASE 
 
3.1 Introduction 
Eicosanoids are a class of inflammatory signaling molecules derived from a common 
precursor, arachidonic acid. There are over 100 different eicosanoids, which can be further 
classified into four categories: prostaglandins, leukotrienes, prostacyclins, and thromboxanes. 
Eicosanoids have both pro- and anti-inflammatory functions, and therefore these lipids have 
roles in numerous disease states such as cancer, diabetes, rheumatoid arthritis, asthma, and 
cardiovascular disease [144-152]. 
The biosynthesis of eicosanoids is triggered in response to a variety of inflammatory 
signals (e.g. cytokines, growth factors, mechanical trauma) in which AA is liberated from the sn-
2 position of membrane phospholipids by a phospholipase A2 enzyme. In most cases, this initial 
rate limiting step in eicosanoid biosynthesis is started by the activation of group IVA 
phospholipase A2 (cPLA2α) [139].  This activation of cPLA2α in cells requires the association of 
the enzyme with intracellular membranes in a Ca2+-dependent manner, which is mediated by 
the N-terminal C2 domain of the enzyme [99,110-112].  Previously, our group has demonstrated 
that cPLA2α is activated by direct binding of the C2 domain to ceramide-1-phosphate (C1P) 
[118,129,131,132].  This direct binding of the C2 domain to C1P increases the residence time of 
cPLA2α on the cellular membranes, thereby increasing the catalytic ability of the enzyme.  The 
C1P binding site on the enzyme consists of at least three cationic amino acids, R57, K58, and 
R59, which are present in the β-groove of cPLA2α [126,240].  Mutation of these amino acids to 
alanine has no effect on basal activity or the binding to other phospholipids, but the association 
of the enzyme with C1P is lost in vitro. In cells, this mutant of cPLA2α is not activated in 
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response to inflammatory agonists demonstrating the requirement of the cPLA2α/C1P 
interaction in eicosanoid biosynthesis [118,240].   
C1P is produced by phosphorylation of ceramide by ceramide kinase, and as the 
C1P/cPLA2α interaction is required for eicosanoid production, a role for CERK was 
hypothesized in this biosynthesis cascade.  In this regard, our laboratory previously 
demonstrated that downregulation of CERK by siRNA inhibited eicosanoid production induced 
by a variety of agonists [118,88,127].  However, genetic ablation of CERK in mice has produced 
mixed results, both ex vivo and in vivo.  For example, Graf et al. found that the CERK-/- animals 
were sensitive to both antigen (Ag)-induced and serum transfer-induced arthritis in contrast to 
the cPLA2α knockout suggesting that cPLA2α pathways are fully functional in the CERK-/- 
animals [96].  In contrast, this same laboratory group reported that basal PGE2 synthesis was 
reduced in the bronchoalveolar (BAL) fluid of CERK-/- mice [98].  Importantly, these studies 
showed an appreciable amount of D-e-C18:1/16:0 C1P was still present in the CERK-/- cells, and 
other C1P subspecies were not characterized.  Igarashi and co-workers also generated a CERK 
knockout mouse and demonstrated a minor effect on total C1P levels [97].  Hence, these 
reports provided evidence that there is at least one alternative pathway for the synthesis of C1P 
in addition to CERK [96].  This alternative pathway of C1P production is still unknown, and 
developmental compensation via these uncharacterized pathways was possible as the total 
C1P levels were only minorly affected as reported by both Igarashi and co-workers and Graf 
and co-workers [96,97].  Furthermore, only a few eicosanoids have been characterized for 
CERK-/- cells opening the possibility of CERK regulation of uncharacterized eicosanoids. 
   In this regard, we examined the effect of genetic ablation of CERK on both C1P 
subspecies production and eicosanoid synthesis by HPLC-ESI-MS-MS. A decrease in several 
subspecies of C1P was observed for an overall moderate, but significant decrease in total 
ceramide-1-phosphate in ex vivo cells from the CERK-/- animal.  Furthermore, tissue culture 
conditions (percent of serum in the media) had significant effects on compensating for the loss 
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of C1P induced by the genetic ablation of CERK.  Interestingly, novel C1P subspecies were 
observed in the CERK-/- cells in comparison to wild-type cells verifying the hypothesis of 
developmental compensation via upregulation of a separate anabolic pathway.  We also 
demonstrate that ablation of CERK produces a dysfunction in basal eicosanoid synthesis as 
well as in the eicosanoid response to the calcium ionophore, A23187.  Lastly, we demonstrate 
that the CERK-/- mouse is not dysregulated in eicosanoid production induced by airway hyper-
responsiveness in stark contrast to mice treated with inhaled CERK siRNA.  Overall, the results 
of this study demonstrate that the CERK-/- mouse model has partially compensated when 
examining eicosanoid synthesis ex vivo and in vivo. 
 
3.2 Materials and Methods 
3.2.1 Cell culture 
Primary mouse embryonic fibroblasts (MEFs) were isolated from 13 or 14 days pregnant 
mice as previously described [238] and maintained for three or less passages in high glucose 
Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 20% fetal bovine serum 
(Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at standard incubation conditions. For 
immortalized MEFs, the cells were passaged every 3 days, and after 20 serial passages of the 
primary MEFs, immortalized MEFs were obtained.   Immortalized MEFs were grown in high 
glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum (Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at 5% CO2 at 37°C and 
passaged every 2 days.   Bone marrow derived macrophages (BMDMs) were isolated as 
previously described [241].  Briefly, BALB/c mice were sacrificed, and the femoral and tibial 
marrow were flushed with sterile PBS using a 27-gage needle. Red blood cells were then 
removed by osmotic shock. The cells were resuspended in culture medium supplemented with 
15% FBS and 10 ng/mL M-CSF (hereafter BMDM medium), seeded at a density of 2.0×105 cells 
per cm2, and incubated at 37°C in a humidified incubator with 5% CO2. The following day, 
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adherent cells were discarded, while non-adherent cells were centrifuged at 1000×g for 5 min. 
Cell pellet was re-suspended in fresh BMDM medium, and allowed to further differentiate. On 
day 3, fresh BMDM medium was added to the culture dish. On day 6, the non-adherent cells 
were discarded, and a fresh BMDM medium was added. 
 
3.2.2 Baseline eicosanoid experiments   
3.2.2.1 Short-term (4 hours)  
MEFs (2 × 106) were plated in 10-cm dishes in the appropriate medium and grown under 
standard incubator conditions overnight.  The next morning, the medium was removed and 
replaced with high glucose DMEM supplemented with 2% FBS for two hours.  At the end of the 
two hour time point, the medium was removed, and fresh medium (high glucose DMEM, no FBS 
supplement) was added to the cells.  The cells were then incubated for an additional four hours.  
At the end of the four hour treatment, the medium was collected and the cells were harvested 
for analysis.  For 10% FBS supplemented media, the cells were rinsed with fresh 10% serum, 
and then fresh medium (high glucose DMEM, 10% FBS supplement) was added to the cells.  
The cells were also incubated for four hours, medium was collected, and cells harvested for 
analysis. 
3.2.2.2. Long-term (24 hours) 
BMDM cells were plated in 10 cm dishes in the appropriate medium and grown under 
standard conditions overnight.  The next day, the media was removed and replaced with 
medium supplemented with 2% FBS for two hours.  After two hours, the media was removed 
and fresh media with 10% FBS supplement was added to the cells.  The cells were incubated 
for 24 hours.  At the end of the 24 hour treatment, the media was collected, and cells harvested 
for analysis. 
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3.2.3 A23187 treatment experiments   
MEFs (2 × 106) were plated on 10-cm plates in the appropriate medium and grown under 
standard incubator conditions overnight.  The next day, the medium was removed and replaced 
with high glucose DMEM with no FBS supplement for two hours.  At the end of the two hour 
time point, the medium was removed, and cells were treated in high glucose DMEM (no FBS 
supplement) with A23187 (5 µM) (Sigma-Aldrich), DMSO (1:5000) (Sigma-Aldrich), or medium 
for 5 minutes.  At the end of the five minute treatment, the medium was collected, and the cells 
were harvested for analysis. 
 
3.2.4 Airway hyper-responsiveness  
Wild-type BALB/c and CERK-/- mice (BALB/c background, littermates) were obtained 
from Dr. Frederic Bornancin of Novartis International and utilized for these studies [96].  Mice 
were i.p. injected on Day 1 and Day 5 with ovalbumin (OVA) (50 µg) while control mice received 
saline sham injections at the same timepoints.  For in vivo downregulation of ceramide kinase, 
wild-type BALB/c mice were i.p injected with control or CERK siRNA on Day 13 (1 µg/g body 
weight) as described [242-244] and briefly below.  To induce the phenotype, mice were 
challenged with aerosolized OVA (1% in PBS for 60 minutes) on Days 14-20.  On Day 21 (10 
hours post-challenge), mice were sacrificed, and BAL fluid was collected. BAL fluid was 
evaluated for eicosanoid production via enzyme-linked immunosorbent assays (ELISAs).  Cell 
populations were evaluated via H&E staining.  For in vivo downregulation of ceramide kinase, 
mice were i.p. injected with control or CERK siRNA (OnTarget siStable, Dharmacon) on Day 13 
(1 µg/g body weight).  Prior to administration, siRNA was bound to siPORT Amine transfection 
reagent according to instructions from the manufacturer.  Briefly, 45 µL siPORT Amine was 
combined with 110 µL saline and was incubated at room temperature for 30 minutes.  45 µL of 
siRNA was then incubated with the siPORT Amine solution for 30 minutes.  The siPORT Amine 
siRNA solution was administered in a total volume of 200 µL. 
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3.2.5 Analysis of ceramide-1-phosphate levels in mouse plasma  
Blood was collected from mice via heart puncture into a syringe containing EDTA (100 
µL) to prevent clotting.  Whole blood was transferred to a glass tube and then centrifuged at 
1000 rpm for 10 minutes to separate plasma.  Plasma was collected and transferred to a clean 
glass tube.  50 µL of plasma was extracted according to the C1P/Sphingolipid analysis protocol 
described below, and previously described by our laboratory [240]. 
 
3.2.6 Eicosanoid detection 
MEFs (2 × 106) were plated on 10-cm plates in the appropriate medium and grown under 
standard incubator conditions overnight. The next day cells were subjected to the relevant 
treatment.  After treatment, the plates were placed on ice, and the medium and cells were 
collected for eicosanoid analysis.   
Eicosanoids were extracted from the collected medium using a solid phase extraction 
method and analyzed as described by Blaho et al. [143] with slight modifications as reported by 
our laboratory [237].  Briefly, to 4 ml of the medium, 100 µl of internal standard containing the 
following deuterated eicosanoids was added (100 pg/µl, 10 ng total): (d4) 6k PGF1α, (d4) PGF2α, 
(d4) PGE2, (d4) PGD2, (d8) 5-hydroxyeicosatetranoic acid (5-HETE), and (d8) Arachidonic Acid.  
400 µl of 10% methanol and 20 µl of glacial acetic acid were also added to the samples. Strata-
X SPE columns (Phenomenex) were washed with 2 ml methanol and then 2 ml of dH2O.  The 
samples were applied, and then the sample vials were rinsed with 2 ml of 5% MeOH, which was 
then applied to the columns.  The eicosanoids were eluted with 2 ml isopropanol.  The eluent 
was dried under vacuum and the samples were reconstituted in 100 µl of 50:50 EtOH:dH2O for 
LC/MS/MS analysis. 
Eicosanoids were extracted from the collected cells via the following procedure.  200 µL 
of cold PBS was added to each plate and cells were scraped and added to a glass tube for 
extraction.  100 µl of internal standard solution containing the following deuterated eicosanoids 
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was added to each sample (100 pg/µl, 10 ng total): (d4) 6k PGF1α, (d4) PGF2α, (d4) PGE2, (d4) 
PGD2, (d8) 5-hydroxyeicosatetranoic acid (5-HETE), and (d8) Arachidonic Acid.  1 mL of ethanol 
was added to each sample and samples were sonicated on ice for approximately one minute.  
Cell extracts were gently shaken at 4°C overnight.  Samples were then centrifuged to pellet cell 
debris and supernatants were transferred to clean glass tubes.  The supernatant was dried 
under vacuum and the samples were reconstituted in 100 µl of 50:50 EtOH:dH2O for LC/MS/MS 
analysis. 
The reconstituted eicosanoids were analyzed via HPLC ESI-MS/MS.  A 30 minute 
reversed-phase LC method utilizing a Kinetex C18 column (100 x 2.1mm, 2.6 µm) was used to 
separate the eicosanoids at a flow rate of 200 µl/min at 50°C.  The column was equilibrated with 
100% Solvent A (acetonitrile:water:formic acid (40:60:0.02, v/v/v)) for five minutes and then 10 
µl of sample was injected.  100% Solvent A was used for the first minute of elution.  Solvent B 
(acetonitrile:isopropanol (50:50, v/v)) was increased in a linear gradient to 25% Solvent B to 3 
minutes, to 45% until 11 minutes, to 60% until 13 minutes, to 75% until 18 minutes, and to 100% 
until 20 minutes.  100% Solvent B was held until 25 minutes, then was decreased to 0% in a 
linear gradient until 26 minutes, and then held until 30 minutes.  The eicosanoids were then 
analyzed using a tandem quadrupole mass spectrometer (ABI 4000 Q-Trap®, Applied 
Biosystems) via multiple-reaction monitoring in negative-ion mode.  Eicosanoids were monitored 
using precursor → product multiple reaction monitoring (MRM) pairs.  The mass spectrometer 
parameters used were: Curtain Gas: 30; CAD: High; Ion Spray Voltage: -3500V; Temperature: 
500°C; Gas 1: 40; Gas 2: 60; Declustering Potential, Collision Energy, and Cell Exit Potential 
vary per transition.  Multiple reaction monitoring transitions utilized for the eicosanoids can be 
found in Table 3-1. 
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Table 3-1. Multiple reaction monitoring pairs utilized for eicosanoid analysis. 
Species Precursor Ion (m/z) Product Ion (m/z) 
PGF2α 353 193 
PGF2α-d4 357 197 
PGE2 351 271 
PGE2-d4 355 275 
PGD2 351 271 
PGD2-d4 355 275 
LTB4 335 195 
LTE4 438 235 
6-keto PGF1α 369 163 
6-keto PGF1α-d4 373 167 
PGI2 351 214 
PGJ2 333 233 
5-HETE 319 115 
5-HETE-d8 327 116 
8-HETE 319 155 
11-HETE 319 167 
12-HETE 319 179 
15-HETE 319 113 
20-HETE 319 145 
Arachidonic Acid 303 259 
Arachidonic Acid-d8 311 267 
 
 
3.2.7 Ceramide-1-phosphate/sphingolipid analysis 
MEFs (2 × 106) or BMDMs were plated on 10-cm plates in the appropriate medium and 
grown under standard incubator conditions overnight. The next day cells were subjected to the 
relevant treatment.  After treatment, the plates were placed on ice, cells washed twice with ice-
cold PBS, and cells harvested by scraping in 200 µl of PBS followed by sonication to obtain a 
homogenous mixture. Lipids were extracted from the remaining cells using a modified Bligh and 
Dyer method and analyzed as described by Wijesinghe et al. [88]. Briefly, to 200 µl of the cells 
in PBS, 1.5 ml of 2:1 methanol:chloroform was added. The samples were spiked with 500 pmol 
of d18:1/12:0 C1P, sphingomyelin, ceramide, and monohexosylceramide as the internal standard 
(Avanti). The mixture was sonicated to disperse the cell clumps and incubated for six hours at 
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48 °C. The samples were then sonicated, followed by centrifugation to separate particulates.  
The extracts were then dried down and reconstituted in methanol.  The reconstituted samples 
were then sonicated, incubated at 48°C for 15 minutes, vortexed, and then incubated for an 
additional 15 minutes at 48°C.  The samples were then centrifuged to separate particulates and 
used for analysis of C1P, Ceramide, Sphingomyelin, and Monohexosylceramide. The lipids 
were separated using a Kinetix C18 column (50 x 2.1 mm, 2.6 µm) (Phenomenex) on a 
Prominence high performance liquid chromatography system (Shimadzu) and eluted using a 
linear gradient (solvent A, 58:41:1 CH3OH/water/HCOOH 5 mM ammonium formate; solvent B, 
99:1 CH3OH/HCOOH 5 mM ammonium formate, 20–100% B in 3.5 min and at 100% B for 4.5 
min at a flow rate of 0.4 ml/min at 60 °C). Electrospray ionization with tandem mass 
spectroscopy using an API 4000 QTRAP instrument (Applied Biosystems, MDS Sciex) was 
used to detect C1P, ceramide, sphingomyelin, and monohexosylceramide under positive 
ionization.  Multiple reaction monitoring transitions utilized for C1P, ceramide, sphingomyelin, 
and monohexosylceramide can be found in Table 3-2.  
 
Table 3-2. Multiple reaction monitoring pairs and mass spectrometer compound-specific 
settings utilized for sphingolipid analysis. 
 
Species Precursor Ion (m/z) Product Ion (m/z) DP CE 
d18:1/12:0 Ceramide 482.6 264.4 50.0 41.0 
d18:1/12:0 C1P 562.4 264.4 50.0 41.0 
d18:1/12:0 MonoHex 644.6 264.4 50.0 41.0 
d18:1/12:0 SM 647.7 184.4 50.0 41.0 
d18:1/14:0 Ceramide 510.7 264.4 50.0 43.5 
d18:1/14:0 C1P 590.4 264.4 50.0 43.5 
d18:1/14:0 MonoHex 672.6 264.4 50.0 43.5 
d18:1/14:0 SM 675.7 184.4 50.0 43.5 
d18:1/16:0 Ceramide 538.7 264.4 50.0 46.0 
d18:1/16:0 C1P 618.5 264.4 50.0 46.0 
d18:1/16:0 MonoHex 700.7 264.4 50.0 46.0 
d18:1/16:0 SM 703.8 184.4 50.0 46.0 
d18:0/16:0 Ceramide 540.7 266.4 50.0 46.0 
d18:0/16:0 C1P 620.5 266.4 50.0 46.0 
d18:0/16:0 MonoHex 702.5 266.4 50.0 46.0 
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Species Precursor Ion (m/z) Product Ion (m/z) DP CE 
d18:0/16:0 SM 705.8 184.4 50.0 46.0 
d18:1/18:1 Ceramide 564.7 264.4 50.0 48.5 
d18:1/18:1 C1P 644.5 264.4 50.0 48.5 
d18:1/18:1 MonoHex 728.7 264.4 50.0 48.5 
d18:1/18:1 SM 731.8 184.4 50.0 48.5 
d18:1/18:0 Ceramide 566.7 264.4 50.0 48.5 
d18:1/18:0 C1P 646.5 264.4 50.0 48.5 
d18:1/18:0 MonoHex 730.7 264.4 50.0 48.5 
d18:1/18:0 SM 733.8 184.4 50.0 48.5 
d18:1/20:0 Ceramide 594.7 264.4 50.0 51.0 
d18:1/20:0 C1P 674.4 264.4 50.0 51.0 
d18:1/20:0 MonoHex 756.7 264.4 50.0 51.0 
d18:1/20:0 SM 759.9 184.4 50.0 51.0 
d18:1/22:0 Ceramide 622.8 264.4 50.0 53.5 
d18:1/22:0 C1P 702.7 264.4 50.0 53.5 
d18:1/22:0 MonoHex 784.8 264.4 50.0 53.5 
d18:1/22:0 SM 787.9 184.4 50.0 53.5 
d18:1/24:1 Ceramide 648.9 264.4 50.0 56.0 
d18:1/24:1 C1P 728.6 264.4 50.0 56.0 
d18:1/24:1 MonoHex 810.9 264.4 50.0 56.0 
d18:1/24:1 SM 813.9 184.4 50.0 56.0 
d18:1/24:0 Ceramide 650.9 264.4 50.0 56.0 
d18:1/24:0 C1P 730.6 264.4 50.0 56.0 
d18:1/24:0 MonoHex 812.9 264.4 50.0 56.0 
d18:1/24:0 SM 815.9 184.4 50.0 56.0 
d18:1/26:1 Ceramide 676.9 264.4 50.0 58.5 
d18:1/26:1 C1P 756.7 264.4 50.0 58.5 
d18:1/26:1 MonoHex 838.9 264.4 50.0 58.5 
d18:1/26:1 SM 841.9 184.4 50.0 58.5 
d18:1/26:0 Ceramide 678.9 264.4 50.0 58.5 
d18:1/26:0 C1P 758.7 264.4 50.0 58.5 
d18:1/26:0 MonoHex 840.9 264.4 50.0 58.5 
d18:1/26:0 SM 843.9 184.4 50.0 58.5 
 
 
3.2.8 3H-arachidonic acid labeling experiments 
3.2.8.1 Pulse-labeling (4 hour) 
MEFs (0.5 x 105) were plated in 24 well plates in the appropriate medium and were 
grown under standard incubation conditions overnight.  The next day, the medium was replaced 
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and 0.25 µCi [3H]-AA was added for an incubation period of 4 hours.  Then the medium was 
collected, and the cells were harvested.  The radioactivity was determined in both the 
supernatants and the cells using a scintillation counter as previously described by our laboratory 
[127,128,130]. 
 
3.2.8.2 Steady-state labeling (A23187)  
MEFs (0.5 x 105) were plated in 24 well plates in the appropriate medium supplemented 
with 0.25 µCi [3H]-AA per well and grown under standard incubation conditions overnight.  The 
next day the cells were washed with PBS (Invitrogen) and then incubated with fresh medium 
containing 0% FBS for two hours.  After two hours, the 0% serum media was removed, and the 
cells were treated with A23187 (5 µM in 0% FBS medium), DMSO (1:5000 in 0% FBS medium), 
or medium for five minutes.  After five minutes, the medium was collected and centrifuged, and 
the cells were harvested.  The radioactivity was determined in both the supernatants and the 
cells using a scintillation counter as previously described by our laboratory [127,128,130,133]. 
 
3.2.9 Immunoblotting 
Western blot analysis was performed as described previously [263,264] using 10 µg of 
protein from each extract. Mouse anti-cPLA2α (1:200) (Santa Cruz) was used to identify the 
protein of interest. Anti β-actin antibody (1:5000) (Cell Signaling) was used as the normalizing 
factor. 
 
3.2.10 Statistical Analysis 
Data from experiments involving the comparison of only two groups are plotted as mean 
± standard deviation.  Significance testing was performed using a two-tailed, independent 
sample t-test to compare means.  For all other studies involving multiple experimental groups, 
measured values are presented as mean ± standard error. One-way ANOVA and Tukey’s post-
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hoc analysis were used for pair-wise comparison of experimental groups.  Analysis was 
performed on statistical software (IBM SPSS statistics 19.0) with p < 0.05 being considered 
significant.  
 
3.2.11 Ethical considerations 
Breeding pairs of the CERK-/- mice (BALB/c background) and wild-type BALB/c 
counterparts were obtained from Dr. Frederick Bornancin of Novartis International (23) and were 
bred kept in the animal care facility at VCU. The mouse studies were undertaken under the 
supervision and approval of the VCU IACUC (Protocol# AM10089) following standards set by 
the Federal and State government. The animal assurance number for VCU is A2381-01.  
 
3.3 Results 
3.3.1 Genetic ablation of ceramide kinase reduces basal ceramide-1-phosphate levels 
 Previously, we confirmed that knockdown of ceramide kinase by siRNA technology 
reduced C1P levels in A549 cells [118] demonstrating that CERK was an anabolic enzyme for 
C1P formation in these cells.  Additionally, Graf and coworkers demonstrated the production of 
C18:1/16:0 C1P was decreased in the genetic ablation model of CERK [96], but only this form was 
examined.  For this study, we examined the effect of genetic ablation of CERK on the levels of 
various C1P subspecies using immortalized CERK-/- murine embryonic fibroblasts (MEFs) in 
comparison to CERK+/+ MEFs.  Using HPLC-ESI-MS-MS, the levels of C18:1/22:0 C1P, C18:1/24:1 
C1P, and C18:1/24:0 C1P in the CERK-/- MEFs were significantly lower than the levels observed in 
the CERK+/+ MEFs (Figure 3-1, Panel A).  For example, C18:1/22:0 C1P was downregulated 
approximately 75% in the CERK-/- MEFs, C18:1/24:1 C1P was downregulated approximately 30%, 
and C18:1/24:0 C1P was downregulated approximately 40%.  Overall, the total amount of C1P was 
downregulated approximately 24% (Figure 3-1, Panel B).  Interestingly, we did not observe a 
significant difference in the amount of C18:1/16:0 C1P when the CERK+/+ and CERK-/- MEFs were 
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compared in contrast to previous reports in ex vivo cells from the CERK-/- mouse [96].  To 
ensure that the C1P downregulation observed in the CERK-/- MEFs was not due to a reduction 
in ceramide, ceramide levels were also analyzed (Figure 3-1, Panel C).  All chain lengths except 
C18:1/22:0 C1P showed an increase in ceramide (Figure 3-1, Panel D).    Monohexosyl ceramide 
levels were also evaluated, and both individual chain lengths and total monohexosyl ceramide 
levels were downregulated (Figure 3-1, Panels E and F).  Finally, sphingomyelin levels were 
evaluated and all chain lengths except C18:1/18:0 SM were found to be upregulated (Figure 3-1, 
Panel G) and an overall increase in total sphingomyelin was observed (Figure 3-1, Panel G). 
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Figure 3-1. Genetic ablation of ceramide kinase reduces basal ceramide-1-phosphate 
levels.  Immortalized MEFs (2 × 106) were plated in 10 cm dishes and incubated under 
standard conditions overnight.  The next morning, the medium was replaced with 2% serum 
medium for two hours and were then changed to 0% serum media for an additional four hours.  
Cells were harvested, extracted and analyzed via HPLC-ESI MS/MS as described in the 
Materials and Methods section to evaluate the levels of C1P. (A) C1P levels by individual chain 
length, (B) total C1P, (C) Ceramide levels by individual chain length, (D) total ceramide, (E) 
Monohexosyl ceramide levels by individual chain length, (F) total monohexosyl ceramide, (G) 
sphingomyelin levels by individual chain length, and (H) total sphingomyelin. (* indicates a 
statistical significance of p<0.01, ** indicates a statistical significance of p<0.001) Data are 
representative of n=6 on at least three separate occasions, plotted as mean ± standard 
deviation.  Significance testing was performed using a two-tailed, independent sample t-test to 
compare means. 
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 To further characterize the levels of C1P subspecies in the CERK ablation model, and 
determine whether immortalization affected the type of C1P produced, the C1P profile was 
determined in primary MEFs as well as in primary bone marrow-derived macrophages (BMDMs) 
for CERK-/- and CERK+/+ mice.  A decrease in C1P was also observed in the primary MEFs, but 
interestingly, the C18:1/16:0 subspecies was the only chain length of C1P that was decreased in 
the CERK-/- cells analogous to the findings of Graf and co-workers [96,86] (Figure 3-2, Panel A).  
Overall, a 51% decrease of C1P was observed in the CERK-/- MEFs (Figure 3-2, Panel B).  As 
with the immortalized MEFs, ceramide, monohexosyl ceramide, and sphingomyelin levels were 
also evaluated.  No significant difference in ceramide, monohexosyl ceramide, or sphingomyelin 
levels were found between the CERK+/+ and the CERK-/- primary MEFs (Figure 3-2, Panels C-
H). 
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Figure 3-2. Genetic ablation of ceramide kinase reduces basal ceramide-1-phosphate 
levels in primary MEFs.  Primary MEFs (2 × 106) were plated in 10 cm dishes and incubated 
under standard conditions overnight.  The next morning, the medium was replaced with 2% 
serum medium for two hours and were then changed to 0% serum media and incubated for four 
hours.  Cells were harvested, extracted and analyzed via HPLC-ESI MS/MS as described in the 
Materials and Methods section to evaluate the levels of C1P. (A) C1P levels by individual chain 
length, (B) total C1P, (C) Ceramide levels by individual chain length, (D) total ceramide, (E) 
Monohexosyl ceramide levels by individual chain length, (F) total monohexosyl ceramide, (G) 
sphingomyelin levels by individual chain length, and (H) total sphingomyelin.  (* indicates a 
statistical significance of p<0.05) Data are representative of n=4 on at least three separate 
occasions, plotted as mean ± standard deviation.  Significance testing was performed using a 
two-tailed, independent sample t-test to compare means.   
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In BMDMs, both C18:1/16:0 C1P and C18:1/18:0 C1P were significantly reduced in the CERK-/- 
cells (Figure 3-3, Panel C) with a total reduction in C1P similar to that of primary MEFs (e.g. an 
approximately 45% reduction in total C1P in the CERK-/- cells) (Figure 3-3, Panel D).  A 
decrease in monohexosyl ceramides was also found in the CERK-/- cells (Figure 3-3, Panel E 
and F).  Overall, there was no significant difference in total sphingomyelin, though a few of the 
longer chain lengths did show a significant decrease in the CERK-/- cells (Figure 3-3, Panels G 
and H).  These data demonstrate that CERK is a major regulator of C1P biosynthesis, but the 
specific chain lengths of C1P subspecies produced by CERK varies in response to 
immortalization and between cell types.     
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Figure 3-3. Genetic ablation of ceramide kinase reduces basal ceramide-1-phosphate 
levels in primary BMDMs.  BMDMs (2 × 106) were plated in 10 cm dishes and incubated under 
standard conditions overnight.  The next morning, the medium was replaced with 2% serum 
medium for two hours and were then changed to fresh 10% serum media and incubated for 24 
hours.  Cells were harvested, extracted and analyzed via HPLC-ESI MS/MS as described in the 
Materials and Methods section to evaluate the levels of C1P. (A) C1P levels by individual chain 
length, (* indicates a statistical significance of p<0.001), (B) total C1P, (C) Ceramide levels by 
individual chain length, (D) total ceramide, (E) Monohexosyl ceramide levels by individual chain 
length (* indicates a statistical significance of p<0.05, ** indicates a statistical significance of 
p<0.01), (F) total monohexosyl ceramide (* indicates a statistical significance of p<0.05), (G) 
sphingomyelin levels by individual chain length (* indicates a statistical significance of p<0.05), 
and (H) total sphingomyelin. Data are representative of n=3 on at least two separate occasions, 
plotted as mean ± standard deviation.  Significance testing was performed using a two-tailed, 
independent sample t-test to compare means.   
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3.3.2 Genetic ablation of ceramide kinase affects basal eicosanoid synthesis 
Previously, we have shown that the association of CERK-derived C1P with cPLA2α is 
required for the synthesis of eicosanoids in response to inflammatory agonists [118].  Therefore, 
we chose to characterize CERK ablation models for eicosanoid production.  First, we examined 
the basal eicosanoid production produced by immortalized MEFs from CERK+/+ mice using 
HPLC-ESI-MS/MS.  Of the 15 eicosanoids examined, six were detected in quantifiable amounts 
(Table 3-3).   
 Specifically, arachidonic acid, PGE2, PGF2α, 6-keto PGF1α, 5-HETE and 11-HETE were 
basally produced in appreciable amounts by CERK+/+ MEFs.  Importantly, the production these 
eicosanoids were significantly reduced in CERK-/- cells with the exception of PGF2α, which was 
surprisingly increased in the CERK-/- MEFs (Figure 3-4 and Table 3-3).   
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Table 3-3. Eicosanoids produced by Immortalized MEFs in 0% Serum. 
Eicosanoid CERK+/+           
(ng/mL media) 
CERK-/-            
(ng/mL media) 
% Control 
(CERK+/+) Arachidonic Acid 0.48 0.16 33% 
PGE2 0.22 0.16 71% 
PGD2 - - ND 
PGF2α 0.08 0.11 145% 
6-keto PGF1α 0.92 0.10 11% 
PGJ2 - - ND 
PGI2 - - ND 
5-HETE 0.05 0.02 44% 
8-HETE - - ND 
11-HETE 0.22 0.11 52% 
12-HETE - - ND 
15-HETE - - ND 
20-HETE - - ND 
LTB4 - - ND 
LTE4 - - ND 
  ND – Not detected 
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Figure 3-4. Genetic ablation of ceramide kinase induces a loss in the production of basal 
eicosanoids.  Immortalized MEFs (2 × 106) were plated in 10 cm dishes and incubated under 
standard conditions overnight.  The next morning, the medium was replaced with 2% serum 
medium for two hours and were then switched to 0% serum media and incubated for four hours.  
Media was then collected and analyzed via HPLC-ESI MS/MS as described in the Materials and 
Methods section to evaluate the levels of (A) arachidonic acid, (B) PGE2, (C) PGF2α, (D) 6-keto 
PGF1α, (E) 5-HETE, and (F) 11-HETE.  Data are representative of n=3 on at least three 
separate occasions, plotted as mean ± standard deviation.  Significance testing was performed 
using a two-tailed, independent sample t-test to compare means.    
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For example, the levels of both 5-HETE and 11-HETE were reduced by approximately 50% in 
the media from the CERK-/- MEFs compared to CERK+/+ MEFs, while PGE2 was reduced 
approximately 30%.  Arachidonic acid and 6-keto PGF1α demonstrated more dramatic 
decreases of approximately 67% and 90%, respectively.  PGF2α presented with an upregulation 
of approximately 45% higher concentration in the media for the CERK-/- MEFs compared to the 
wild type MEFs. As it is possible that genetic ablation of ceramide kinase and therefore reduced 
C1P levels could affect secretion and release of eicosanoids, cellular levels of eicosanoids were 
examined.  Levels of cellular eicosanoids were either unchanged between the CERK+/+ and 
CERK-/- MEFs or the cellular levels corresponded with the media results (Figure 3-5).   
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Figure 3-5. Genetic ablation of ceramide kinase induces a loss in the production of basal 
eicosanoids in cells.  Immortalized MEFs (2 × 106) were plated in 10 cm dishes and incubated 
under standard conditions overnight.  The next morning, the medium was replaced with 2% 
serum medium for two hours and were then switched to 0% serum media and incubated for four 
hours.  Cells were then collected, extracted, and analyzed via HPLC-ESI MS/MS to evaluate the 
levels of (A) 6-keto PGF1α, (B) PGF2α, and (C) arachidonic acid.  Data are representative of 
n=6, plotted as mean ± standard deviation.  Significance testing was performed using a two-
tailed, independent sample t-test to compare means.  
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The dysfunction in eicosanoid synthesis was also observed in the primary CERK-/- 
MEFs, although the reduction in basal eicosanoid synthesis was of a lesser extent.  For 
example, arachidonic acid and 6-keto PGF1α demonstrated the most robust decrease in the 
immortalized MEFs (67% and 89%, respectively), but arachidonic acid and 6-keto PGF1α 
demonstrated only approximately 41% and 20% reduction, respectively, in the primary CERK-/- 
MEFs.  5-HETE and 11-HETE were downregulated approximately 40%, and both PGE2 and 
PGD2 were downregulated approximately 25% (Figure 3-6 and Table 3-4).   
 
Table 3-4. Eicosanoids produced by Primary MEFs in 0% Serum. 
Eicosanoid CERK+/+ 
(ng/mL media) 
CERK-/-            
(ng/mL media) 
% Control 
(CERK+/+) Arachidonic Acid 2.69 1.59 59% 
PGE2 1.14 0.86 75% 
PGD2 0.05 0.03 73% 
PGF2α 0.20 0.19 94% 
6-keto PGF1α 1.10 0.88 80% 
PGJ2 - - ND 
PGI2 - - ND 
5-HETE 0.10 0.06 57% 
8-HETE - - ND 
11-HETE 0.86 0.67 61% 
12-HETE - - ND 
15-HETE - - ND 
20-HETE - - ND 
LTB4 - - ND 
LTE4 - - ND 
  ND – Not detected 
 
Interestingly, PGF2α levels were not shown to be increased in primary CERK-/- cells, but the 
PGF2α levels did not demonstrate a significant difference between wild type CERK and CERK-/- 
cells.   
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Figure 3-6. Genetic ablation of ceramide kinase induces a loss in the production of basal 
eicosanoids in primary MEFs.   Primary MEFs (2 × 106) were plated in 10 cm dishes and 
incubated under standard conditions overnight.  The next morning, the medium was replaced 
with 2% serum medium for two hours and were then switched to 0% serum media and 
incubated for four hours.  Media was then collected and analyzed via HPLC-ESI MS/MS using 
the method described in the Materials and Methods section to evaluate the levels of (A) 
arachidonic acid, (B) PGE2, (C) PGD2, (D) PGF2α, (E) 6-keto PGF1α, (F) 5-HETE, and (G) 11-
HETE.  Data are plotted as mean ± standard deviation.  Significance testing was performed 
using a two-tailed, independent sample t-test to compare means     
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Additionally we wanted to ensure the dysregulation in eicosanoid synthesis was not due 
to a downregulation of cPLA2α protein expression in the cells.  We harvested cells and 
evaluated cPLA2α levels and found no difference in the level of cPLA2α between the CERK+/+ 
and the CERK-/- MEFs (Figure 3-7).  These results demonstrate that there is an inherent basal 
deficiency in eicosanoid production in the CERK-/- cells, but immortalization significantly alters 
the extent of the deficiency.   
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Figure 3-7. Loss in the production of basal eicosanoids in CERK-/- cells is not due to a 
difference in cPLA2α levels.  Primary MEFs (2 × 106) were plated in 10 cm dishes and 
incubated under standard conditions overnight.  The next morning, cells were switched to fresh 
10% serum media and incubated for four hours.  Cells were collected for protein and protein 
levels were evaluated via western blot as described in the Materials and Methods section to 
evaluate the level of cPLA2α.  β-actin serves as the loading control.   
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After observing the differences in the MEFs, we next determined if these effects were 
cell-type specific.  Therefore, we again utilized primary BMDMs obtained from both CERK+/+ and 
CERK-/- mice (Figure 3-8 and Table 3-5).   
 
Table 3-5. Eicosanoids produced by primary Bone Marrow-Derived Macrophages. 
Eicosanoid CERK+/+                  
(ng/µg protein) 
CERK-/-                      
(ng/µg protein) 
% Control 
(CERK+/+) Arachidonic Acid 16.86 3.63 22% 
PGE2 0.33 0.15 45% 
PGD2 - - ND 
PGF2α 1.04 0.72 70% 
6-keto PGF1α - - ND 
PGJ2 - - ND 
PGI2 - - ND 
5-HETE 7.21 1.26 18% 
8-HETE 0.65 0.19 29% 
11-HETE 34.47 10.27 30% 
12-HETE 2.02 0.52 26% 
15-HETE 1.80 0.40 22% 
20-HETE - - ND 
LTB4 - - ND 
LTE4 - - ND 
  ND – Not detected 
 
All eight eicosanoids produced at detectable levels in the media demonstrated significant 
reductions in levels in the CERK-/- BMDMs.  Arachidonic acid, 5-HETE, 12-HETE, and 15-HETE 
demonstrated the most significant reductions of approximately 80%.  PGE2 demonstrated an 
approximately 55% reduction in the CERK-/- cells, and both PGF2α and 11-HETE demonstrated 
approximately 30% reductions.  These results suggest that the overall deficiency in eicosanoid 
production induced by the loss of CERK translates to multiple cell types. 
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Figure 3-8. Genetic ablation of ceramide kinase induces a loss in the production of basal 
eicosanoids in primary BMDMs.  BMDM cells (2 × 106) were plated in 10 cm dishes and 
incubated under standard conditions overnight.  The next morning, the medium was replaced 
with 2% serum medium for two hours and were then switched to fresh 10% serum media and 
incubated for 24 hours.  Media was then collected and analyzed via HPLC-ESI MS/MS using 
the method described in the Materials and Methods section to evaluate the levels of (A) 
arachidonic acid, (B) PGE2, (C) PGF2α, (D) 5-HETE, (E) 8-HETE, (F) 11-HETE, (G) 12-HETE, 
and (H) 15-HETE.   Cells were collected and analyzed via HPLC-ESI MS/MS using the method 
described in the Materials and Methods section to evaluate the levels of ceramide. (I) Ceramide 
levels by individual chain length and (J) total ceramide. Data are representative of n=4 on at 
least two separate occasions, plotted as mean ± standard deviation.  Significance testing was 
performed using a two-tailed, independent sample t-test to compare means. 
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 Next, the effects of serum in the tissue culture media were examined as previous 
reported studies with CERK-/- cells utilized 10% serum in the culture media [148].  We surmised 
that the C1P present in the FBS used to supplement tissue culture media could affect both C1P 
and eicosanoid levels.  In this regard, the quantities of the various chain lengths of C1P were 
again examined in the wild type and the CERK-/- MEFs cultured in 10% serum (Figure 3-9).   
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Figure 3-9.  Tissue culture conditions modulate the compensation of C1P levels in CERK-
/-
 MEFs.  MEFs (2 × 106) were plated in 10 cm dishes and incubated under standard conditions 
overnight.  Cells were then switched to fresh 10% serum media and incubated for four hours.  
Cells were then collected and analyzed via HPLC-ESI MS/MS as described in the Materials and 
Methods section to evaluate the levels of C1P.  (A) C1P levels by individual chain length(* 
indicates a statistical significance of p<0.01, ** indicates a statistical significance of p<0.001.) 
and (B) total C1P. Data are representative of n=6 on at least three separate occasions, plotted 
as mean ± standard deviation.  Significance testing was performed using a two-tailed, 
independent sample t-test to compare means.   
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Similarly to the C1P levels found when the MEFs were incubated with media containing no 
serum, the levels of C18:1/22:0 C1P, C18:1/24:1 C1P, and C18:1/24:0 C1P were downregulated in the 
CERK-/- MEFs.  However, with the inclusion of 10% FBS in the media, an approximately 2-fold 
upregulation of C18:1/14:0 C1P was observed in the CERK-/- MEFs when compared with the 
CERK+/+ MEFs.  When the levels of C1P are compared between the no serum treatment and 
the 10% serum treatment, C18:1/16:0 C1P appears to have higher levels in 10% serum.  In 
contrast, the addition of serum in the media reduced the C18:1/24:0 levels found in both cell types. 
Overall, these data illustrating the differences in C1P levels based upon the amount of serum in 
the media suggest that MEFs have the ability to partially compensate for C1P deficiency.  
To determine if the increase of C1P induced by serum correlated with an effect on 
eicosanoid biosynthesis, basal eicosanoid production was again examined.  Of the 15 
eicosanoids examined, 11 were produced in quantifiable amounts when immortalized MEFs 
were treated with 10% serum in contrast to the six detected when treated with 0% serum 
(Figure 3-10 and Table 3-6).   
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Table 3-6. Eicosanoids produced by Immortalized MEFs in 10% Serum. 
Eicosanoid CERK+/+ 
(ng/mL media) 
CERK-/-            
(ng/mL media) 
% Control 
(CERK+/+) Arachidonic Acid 7.55 6.06 80% 
PGE2 17.35 4.38 25% 
PGD2 0.57 1.05 185% 
PGF2α 0.50 0.90 180% 
6-keto PGF1α 37.62 1.53 4% 
PGJ2 0.47 0.30 64% 
PGI2 - - ND 
5-HETE 0.24 0.22 91% 
8-HETE 0.06 0.05 92% 
11-HETE 9.93 4.66 47% 
12-HETE 0.64 0.60 94%a 
15-HETE 0.17 0.09 51% 
20-HETE - - ND 
LTB4 - - ND 
LTE4 - - ND 
  ND – Not detected, aNot Significant 
 
Specifically, arachidonic acid, PGE2, PGD2, PGF2α, 6-keto PGF1α, PGJ2, 5-HETE, 8-HETE, 11-
HETE, 12-HETE, and 15-HETE were basally produced in appreciable amounts by CERK+/+ 
MEFs.  These 11 eicosanoids were also produced in quantifiable amounts in the CERK-/- MEFs.  
The levels of these eicosanoids were again reduced in the CERK-/- cells with the exception of 
PGD2 and PGF2α being produced at higher levels in the CERK-/- MEFs.  The overall levels of 
eicosanoids were significantly upregulated in both cell types with respect to the levels produced 
for basal eicosanoids without FBS supplementation.  Interestingly, the levels of arachidonic 
acid, PGF2α, and 5-HETE were greatly increased when comparing the percent control values 
for CERK-/- MEFs between the 0% serum treatment and the 10% serum treatment (Table 3-6), 
while PGE2 levels were decreased when comparing the percent control values (Table 3-6).   
These results further illustrate the inherent difference of tissue culture conditions on basal 
eicosanoid production in the CERK-/- MEFs when compared to wild type counterparts.  
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Figure 3-10.  Tissue culture conditions modulate eicosanoid levels in CERK-/- MEFs.  
Immortalized MEFs (2 × 106) were plated in 10 cm dishes and incubated under standard 
conditions overnight.  Cells were then switched to fresh 10% serum media and incubated for 
four hours.  Media was then collected and analyzed via HPLC-ESI MS/MS using the method 
described in the Materials and Methods section to evaluate the levels of (A) arachidonic acid, 
(B) PGE2, (C) PGD2, (D) PGF2α, (E) 6-keto PGF1α, (F) PGJ2, (G) 5-HETE, (H) 8-HETE, (I) 11-
HETE, (J) 12-HETE, and (K) 15-HETE.   Data are representative of n=6 on at least three 
separate occasions, plotted as mean ± standard deviation.  Significance testing was performed 
using a two-tailed, independent sample t-test to compare means. 
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After observing the differences in basal eicosanoid synthesis between the CERK+/+ and 
CERK-/- MEFs, we questioned whether the differences in eicosanoid synthesis were due to a 
dysfunction in the uptake of arachidonic acid.  To test this possibility, pulse labeling experiments 
with [3H]-arachidonic acid were undertaken, and no differences in the uptake of arachidonic acid 
into the cells (Figure 3-11) was observed when comparing the CERK+/+ and the CERK-/- MEFs.  
These results demonstrate that the dysfunction in eicosanoid synthesis observed in the CERK-/- 
cells is not due to an issue with arachidonic acid uptake. 
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Figure 3-11.  Eicosanoid dysfunction in CERK-/- cell is not due to a dysfunction of 
arachidonic acid uptake.  MEFs (0.5 x 105) were plated in 24 well plates and were grown to 
confluency under standard incubation conditions overnight.  The next day, the medium was 
replaced and 0.25 µCi [3H]-AA was added to fresh medium with 0% serum for an incubation 
period of 4 hours.  The medium was then collected and centrifuged and the cells were 
harvested.  The radioactivity was determined in both the media and the cells.  Data are 
representative of at least n=3 performed on two separate occasions, plotted as mean ± 
standard deviation.  Significance testing was performed using a two-tailed, independent sample 
t-test to compare means.   
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3.3.3. Genetic ablation of CERK leads to dysfunction of arachidonic acid release and 
eicosanoid synthesis in response to calcium ionophore 
 Previously, our laboratory demonstrated that the interaction between C1P and cPLA2α is 
required for the activation/translocation of cPLA2α in response to inflammatory agonists (e.g. the 
calcium ionophore, A23187).  Due to this requirement of C1P, we hypothesized that the CERK-/- 
cells would be dysfunctional in eicosanoid synthesis in response to A23187.  Wild-type MEFs 
demonstrated a dramatic increase in three of the quantifiable eicosanoids, PGE2, 6-keto PGF1α, 
and 11-HETE in response to A23187.  However, the response of CERK-/- MEFs to A23187 was 
startling reduced in these same eicosanoids with the fold-stimulation of the A23187 response 
significantly inhibited (Figure 3-12 A-C).  No significant differences were observed between the 
no treatment and the DMSO control samples.  These data demonstrate that the production of 
eicosanoids in response to calcium ionophore is dysfunctional in CERK-/- cells. 
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Figure 3-12.  Genetic ablation of ceramide kinase induces a reduction in A23187-induced 
eicosanoid production. MEFs (2 × 106) were plated in 10 cm dishes and incubated under 
standard conditions overnight.  The next morning, the medium was replaced with 0% serum 
medium for two hours and were then dosed with 5 µM A23187, 1:5000 DMSO, or 0% serum 
sham for 5 minutes.  Media was then collected and analyzed via HPLC-ESI MS/MS using the 
method described in the Materials and Methods section to evaluate the levels of eicosanoids.  
(A) PGE2, (B) 6-keto PGF1α, and (C) 11-HETE.  Data are combined results from n=3 performed 
on three separate occasions.  [3H]-Arachidonic Acid uptake and release is shown in media (D) 
with percentage of release shown in (E).  Data are representative of n=3 performed on two 
separate occasions, measured values are presented as mean ± standard error. One-way 
ANOVA and Tukey’s post-hoc analysis were used for pair-wise comparison of experimental 
groups.  Analysis was performed on statistical software (IBM SPSS statistics 19.0) with p < 0.05 
being considered significant. 
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This effect of genetic ablation of CERK on eicosanoid synthesis was confirmed at the 
level of arachidonic acid release using steady-state labeling with [3H]-arachidonic acid.  Both 
CERK+/+ and CERK-/- cells showed a significant increase in [3H]-arachidonic acid release upon 
stimulation with A23187; but as predicted, the amount of arachidonic acid released from CERK-/- 
cells was significantly less than the amount released from the CERK+/+ cells (Figure 3-12 D and 
E).  No significant differences were observed between the no treatment and the DMSO control 
samples.  Therefore, the genetic loss of CERK leads to dysregulation in both basal and induced 
eicosanoid synthesis. 
 
3.3.4 C1P levels are not affected in the plasma of CERK-/- mice 
 There have been reports of few phenotypes in the CERK-/- mice [96-98] in comparison to 
phenotypes found in the cPLA2α knockout mouse [103,137,245-252,164], which is unexpected 
given the importance of the binding of C1P and cPLA2α in the activation of the enzyme and 
resulting eicosanoid synthesis [118].  This lack of phenotypes suggests the possibility that the 
CERK-/- mice may have at least partially compensated for the loss of CERK.  As our ex vivo 
cellular experiments demonstrated that tissue culture conditions modulate the levels of both 
C1P and eicosanoids, we analyzed the C1P profile in plasma from both the CERK+/+ and CERK-
/-
 mice.   
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Figure 3-13.  C1P levels are unchanged in the plasma of CERK-/- mice.  Whole blood was 
collected via heart puncture from both wild type and CERK knockout mice.  Whole blood was 
immediately centrifuged to separate plasma.  Plasma was then extracted as described in the 
Materials and Methods section to evaluate the levels of C1P.  C1P levels are shown for (A) 
specific chain lengths and (B) total C1P.  Data are representative of at least n=4 performed on 
two separate occasions, plotted as mean ± standard deviation.  Significance testing was 
performed using a two-tailed, independent sample t-test to compare means. 
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Interestingly, no significant difference was observed in specific chain lengths of C1P (Figure 3-
13, Panel A) nor total C1P levels (Figure 3-13, Panel B) when comparing plasma from the 
CERK+/+ and CERK-/- mice.  These data indicate that despite ex vivo cells showing reductions in 
C1P levels with loss of CERK, plasma levels of the CERK-/- mice are unaffected.   
 
3.3.5 The CERK-/- mouse has compensated in regards to airway hyper-responsiveness 
As we now hypothesized that the CERK-/- mouse has partially compensated for loss of 
CERK by producing C1P via a separate anabolic pathway, the genetic loss of CERK was 
compared to acute induced-loss of CERK via siRNA in an inflammatory phenotype.  Airway 
hyper-responsiveness was evaluated in relation to the loss of CERK as the cPLA2α knockout 
mouse demonstrated reduced eicosanoid production upon OVA-challenge/rechallenge [103].   
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Figure 3-14.  CERK-/- mice have compensated in regards to airway hyper-responsiveness.  
Mice were IP injected on Day 1 and 5 with OVA (50 µg) and control mice received saline sham 
injections.  To knockdown ceramide kinase, mice were injected with CERK siRNA on Day 13 (1 
µg/g body weight).  To induce the phenotype, the mice were challenged with aerosolized OVA 
(1% in PBS for 60 minutes) on Days 14-20.  After the Day 20 challenge, mice were sacrificed 
with BAL fluid and lungs collected. (A) Schematic of AHR experimental design; (B) Western blot 
depicting CERK knockdown in lungs; BAL fluid was evaluated for eicosanoid production via 
enzyme-linked immunosorbent assays (ELISAs) for (C) PGE2, (D) PGD2, and (E) TXB2; and (F) 
Cells contained in BAL fluid were characterized by H&E staining. Data are representative of n=8 
on at least three separate occasions, measured values are presented as mean ± standard error. 
One-way ANOVA and Tukey’s post-hoc analysis were used for pair-wise comparison of 
experimental groups.  Analysis was performed on statistical software (IBM SPSS statistics 19.0) 
with p < 0.05 being considered significant. 
.   
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OVA was i.p. injected on Day 1 and Day 5, then these mice were rechallenged by 
aerosolized OVA on Days 14-20 (1 hour/day).  siRNA was given to mice via i.p. injection on Day 
13 (Figure 3-14 A), and mice were sacrificed on Day 21 (10 hours post challenge) with the lungs 
and BAL fluid collected.  In our study, siRNA was utilized to knock down ceramide kinase levels 
in the lungs of wild type mice, and these mice were evaluated for airway hyper-responsiveness.  
The CERK siRNA introduced to the mice successfully infiltrated the lung and downregulated the 
production of CERK (Figure 3-14 B).  BAL fluid was evaluated for eicosanoid production via 
ELISA, and three eicosanoids, PGE2, PGD2, and TXB2 were upregulated upon challenge with 
ovalbumin (Figure 3-14 C-E).  In addition, the production of PGE2 and PGD2 was significantly 
decreased with the acute downregulation of CERK when mice were challenged with ovalbumin 
(Figure 3-14 C and D), while the downregulation of CERK had no effect on TXB2 production 
(Figure 3-14 E). Cell infiltration in the BAL fluid was also characterized, and no significant 
differences were observed between control siRNA and CERK siRNA treated mice 
demonstrating that the observed differences were not due to loss of eosinophil infiltration 
(Figure 3-14 F).  This study was then repeated with CERK+/+ and CERK-/- mice, and no 
difference was observed when comparing the eicosanoid production of the CERK+/+ and CERK-/- 
mice in accord with a previous report by Graf and co-workers [98] (data not shown). These data 
demonstrate the genetic ablation of CERK produces different phenotypes in comparison to 
acute downregulation via siRNA treatment. 
 
3.4 Discussion 
In this study, we have demonstrated that CERK-derived C1P is instrumental in the 
production of eicosanoids, corroborating our previous studies illustrating that siRNA 
downregulation of CERK blocks the release arachidonic acid by inhibiting the production of 
CERK-derived C1P [118,127].  As we have shown here, cells derived from the CERK-/- mice 
and tested under reduced serum conditions are dysfunctional in eicosanoid synthesis, both 
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basally and in response to calcium ionophore.  This further illustrates the effects of CERK-
derived C1P on eicosanoid production, and therefore implicates these mediators as players in 
the inflammatory response. Of note, these findings are partially in opposition to the reports by 
Bornancin and co-workers [96,98,95].  Specifically, this group explored how cPLA2α-dependent 
pathways were affected by the genetic ablation of CERK and this laboratory observed similar 
responses of cells derived from both wild type and knockout animals to PMA/Ionomycin 
treatment as well as the susceptibility of the whole animals to arthritis induction by both Ag and 
KRN serum.  As cPLA2α function is imperative in these responses, Bornancin and coworkers 
concluded that cPLA2α-dependent pathways were functional.  However, after this study was 
released, our laboratory reported the C1P binding site on the cPLA2α protein and showed that 
both reduction in C1P and mutation of this binding site reduced the activity of cPLA2α [126].  
These contradictory results gave rise to the current study using cells from the same genetic 
model, and this study demonstrates several differences in approaches that may explain the 
contrasting findings. For example, most of our cellular MEF results demonstrating dysregulation 
in eicosanoids utilized either no serum or low serum environments in comparison to the 
Bornancin study. Indeed, as we increase serum levels, the effect on both total C1P levels and 
the basal generation of eicosanoids becomes partially “rescued”. Furthermore, a novel chain 
length of C1P is increased in the CERK-/- cells, which may account for the minor phenotype on 
eicosanoids observed in a high serum environment. Regardless, MEFs from the CERK-/- mouse 
presented with reduced levels of C1P, and the role of C1P in regulating cPLA2α responses may 
be cell type specific. For example, the C1P levels in BMDMs are several-fold higher than the 
fibroblasts regardless of serum concentration utilized for MEFs, and the effect on basal 
eicosanoids is also more dramatic in BMDMs from CERK-/- cells. Hence, differential effects on 
eicosanoids in regards to C1P may vary greatly from cell-type to cell-type. Indeed, the reports 
by Bornancin and co-workers also used different cell types, specifically primary kidney 
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fibroblasts and peritoneal macrophages [96,86]. Unfortunately, we were unable to obtain 
peritoneal macrophages using thioglycolate in the CERK-/- animals in contrast to CERK+/+. 
Hence, we could not undertake the same studies, and relied on BMDMs for comparison. We 
attribute the lack of macrophage infiltration in response to thioglycolate to the reported 
neutropenia as neutrophils are strongly linked to macrophage infiltration [96]. 
Another difference between the studies is the use of PMA/ionomycin versus our use of only 
calcium ionophore in regards to AA release. PMA drives activation of protein kinase C, which 
has been strongly linked to cPLA2α activation [254-257]. This activation may or may not be 
dependent on C1P, and unpublished findings from our laboratory show that a DAG lipase 
inhibitor is a dramatic stimulator of eicosanoid synthesis without the requirement of C1P. 
Regardless, this study and the Graf studies are not dramatically divergent with technical 
differences explaining many of the contrasting findings for the cell studies.  
As culture conditions, technical details, and differences in cell types may explain the 
incongruent findings between our laboratory and the reports by Bornancin and co-workers, the 
only remaining conundrums in regards to CERK and eicosanoid synthesis is the report by 
Bornancin and co-workers as to the relative lack of phenotypes in the CERK-/- animals for 
eicosanoid biosynthesis as well as the more recent report using a specific CERK inhibitor (NVP-
231) in vitro [95]. In regards to the CERK-/- mouse, this genetic ablation model does not 
demonstrate the phenotypes observed in the cPLA2α knockout mouse (e.g. resistance to 
arthritis induction by both Ag and KRN serum and OVA-induced airway hyper-responsiveness 
(AHR)) with the exception of one report by Bornancin and co-workers showing a reduction in the 
levels of basal PGE2 in the BAL fluid of the CERK-/- mice [96,98]. As a decade of research from 
our laboratory and others has shown cPLA2α to possess a specific C1P-interaction site, we 
hypothesized that the CERK-/- mice were able to demonstrate intact cPLA2α-dependent 
pathways due to an compensation of the whole mouse to the loss of CERK-derived C1P 
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[118,132,131,129,126,240,128,130,133].  For example, no differences in total C1P levels were 
observed in the serum of the mice, which correlates well with C1P data obtained from primary 
hepatocytes [258]. Thus, not all cells produce C1P via CERK, and as our cell studies showed, 
other cells can at least partially compensate for loss of CERK via upregulating novel chain 
lengths of C1P [258]. This effect was also observed by genetic ablation of CERK in HeLa cells 
via zinc-finger nuclease technology [258]. Indeed, the levels of C1P were increased upon 
ablation of CERK in these cells via an unknown anabolic pathway [258]. This type of 
compensation could explain the lack of phenotypes observed in the CERK knockout mouse. 
The hypothesis of the compensation of the CERK-/- mice to loss of C1P is supported by our 
airway hyper-responsiveness (AHR) studies presented in this manuscript. An effect on 
eicosanoid production induced by AHR was observed when CERK was downregulated via 
siRNA, but the same effect was not seen in the evaluation of the CERK-/- mice. These types of 
differences have also been observed in some phenotypes for the genetic ablation model of 
cPLA2α in comparison to the acute inhibition/downregulation of the enzyme by utilization of 
cPLA2α inhibitors and siRNA [259-261].  This difference in results when comparing the CERK-/- 
mice with the CERK downregulated mice (treated with siRNA) is interesting, and there are many 
possibilities for this to be the case.  One possibility is that despite efforts to eliminate the 
possibility of off-target effects, our siRNA may have downregulated an additional RNA species 
in the lungs of the mice.  A more likely possibility is that the timing of CERK 
downregulation/ablation could affect the outcome.  As we have shown through our studies, the 
CERK-/- mice have compensated for the loss of CERK by the time the mice have reached 
adulthood.  With the siRNA downregulation of CERK being an acute response, it is possible that 
the mice did not have enough time to effectively compensate for the downregulation of CERK. 
Overall, our studies highlight the difficulty of examining complex and important pathways in 
mammalian physiology due to compensatory pathways, which highlight the difficulty in 
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understanding the role of cPLA2α, in general, as well as via the activation of lipid co-factors. 
Thus, for examining the role of a protein:lipid interaction, it may be necessary to identify the 
binding site and ablate this site genetically in a mouse to determine function. This may be one 
alternative route to determining the role of a particular bioactive lipid in a particular biology to 
overcome compensatory mechanisms when targeting the biosynthetic pathways.  
As stated previously, there is still the question of the CERK inhibitor (NVP-231) developed 
by Novartis [95]. Bornancin and co-workers reported that treatment of cells with this inhibitor 
had no effect on the stimulation of eicosanoid synthesis by various inflammatory agonists [95]. 
Our laboratory has only sparingly utilized this inhibitor, but concur that the inhibitor dramatically 
reduces total C1P levels with 1hr of treatment in primary MEFs (Figure 3-15).  
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Figure 3-15.  The CERK inhibitor, NVP-231, potently and dramatically lowers the 
synthesis of all chain lengths of C1P, with the exception of C18:1/14:0 C1P. Immortalized 
MEFs (2 × 106) were plated in 10 cm dishes and incubated under standard conditions overnight.  
The next morning, the medium was replaced with 0% serum medium for two hours.  After one 
hour, NVP-231 (CERK inhibitor) was added to the media (200 nM).  After one hour, the media 
was removed and cells were dosed with 5 µM A23187, 1:5000 DMSO, or 0% serum media for 5 
min.  Cells were harvested, extracted and analyzed via HPLC-ESI MS/MS using the method 
described in the Materials and Methods section to evaluate the levels of C1P. (A) C1P levels by 
individual chain length.  (* indicates a statistical significance of p<0.001.).  For C18:1/14:0 C1P, 
pair-wise comparisons indicate that both A23187 and A23187+NVP-231 treatments are 
statistically significant from NT, DMSO, and DMSO+NVP-231 treatments.  For C18:1/16:0 C1P and 
C18:1/24:1 C1P, pair-wise comparisons indicate that both DMSO+NVP-231 and A23187+NVP-231 
treatments are statistically different from NT, DMSO, and A23187 treatments.  (B) Ceramide 
levels by individual chain length. (* indicates a statistical significance of p<0.05, ** indicates a 
statistical significance of p<0.01, *** indicates a statistical significance of p<0.001,).  For C18:1/14:0 
ceramide, pair-wise comparisons indicate that DMSO+NVP-231, A23187, and A23187+NVP-
231 treatments are statistically different from both NT and DMSO treatments.  For C18:1/16:0 
ceramide, pair-wise comparisons indicate NT, DMSO, and A23187+NVP-231 treatments are 
statistically different from DMSO+NVP-231 treatment and DMSO+NVP-231 and A23187 
treatments are statistically different.  For C18:0/16:0 ceramide, pair-wise comparisons indicate 
DMSO+NVP-231 and A23187 treatments are statistically different.  For C18:1/18:1 ceramide, pair-
wise comparisons indicate DMSO and DMSO+NVP-231 treatments are statistically different and 
A23187 and A23187+NVP-231 treatments are statistically different from NT, DMSO, and 
DMSO+NVP-231 treatments.  For C18:1/18:0 ceramide, pair-wise comparisons indicate 
DMSO+NVP-231, A23187, and A23187+NVP-231 treatments are statistically different from NT 
and DMSO treatments.  For C18:1/20:0 ceramide, pair-wise comparisons indicate A23187 is 
statistically different from all other treatments and DMSO+NVP-231 treatment is statistically 
different from NT. For C18:1/22:0 ceramide, pair-wise comparisons indicate DMSO+NVP-231 is 
statistically different from all other treatments.  For C18:1/24:1 ceramide, pair-wise comparisons 
indicate both DMSO+NVP-231 and A23187 treatments are statistically different from all other 
treatments.  For C18:1/24:0 ceramide, pair-wise comparisons indicate NT is statistically different 
from DMSO+NVP-231 treatment; and A23187+NVP-231 treatment is statistically different from 
both DMSO and DMSO+NVP-231 treatments.  For C18:1/26:1 ceramide, pair-wise comparisons 
indicate A23187+NVP-231 is statistically different from all other treatments.  For C18:1/26:0 
ceramide, pair-wise comparisons indicate NT is statistically different from both DMSO and 
A23187 treatments and A23187+NVP-231 treatment is statistically different from both DMSO 
and A23187 treatments.  Data are presented as mean ± standard error. One-way ANOVA and 
Tukey’s post-hoc analysis were used for pair-wise comparison of experimental groups.  Analysis 
was performed on statistical software (IBM SPSS statistics 19.0) with p < 0.05 being considered 
significant. 
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Interestingly, the inhibitor potently and dramatically lowers the synthesis of all chain lengths 
of C1P, with the exception of C18:1/14:0 C1P, in contrast to CERK siRNA [118,88,127] and CERK 
ablation [96,97]. Thus, the CERK inhibitor may also block the currently unknown anabolic 
pathways of C1P biosynthesis as well as CERK. Therefore, this inhibitor may be an excellent 
“tool” to examine C1P biology as the entirety of the C1P anabolic system is possibly blocked. 
What additional targets the inhibitor may be affecting is unknown, but the lack of effect on the 
levels of ceramide suggests that the unknown pathways are not ceramide kinases. On the other 
hand, ceramide may be quickly metabolized to hexosylceramides in MEFs masking any 
increases in ceramide induced by CERK inhibition. As the levels of C1P in comparison to 
ceramide and phosphatidic acid (PA) are very low, a DAG kinase (DAGK) with low activity 
toward ceramide could account for some of the C1P formed in cells, and examination of DAG 
and PA levels in the presence of this inhibitor may be warranted. Furthermore, DAGKθ has high 
homology to CERK [262], and Bornancin and co-workers only examined DAGKα for efficacy 
[95]. Overall, future studies will also include the use of this CERK inhibitor and examining a 
number of cell types and inflammatory agonists under various culture conditions to determine 
whether C1P plays a role in AA release and eicosanoid synthesis. The broad use of this 
inhibitor coupled to findings using a mouse model with the C1P interaction site ablated from 
cPLA2α may finally answer the question as to the role of C1P in regulating cPLA2α activation. 
Furthermore, investigations as to whether this inhibitor will reduce the levels of C1P in cells from 
the CERK-/- mouse as well as the CERK-/- HeLa cells will confirm the inhibition of a separate 
anabolic pathway for C1P formation. Indeed, these cell models may prove useful in defining 
these unknown anabolic pathways for C1P as well as investigate their roles in biological 
mechanisms. 
In conclusion, this study utilizing ex vivo cells supports previous results from our laboratory 
for the role of CERK in the activation of cPLA2α and regulation of eicosanoid synthesis.  This 
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study demonstrates that cells derived from the CERK-/- mice are dysfunctional in eicosanoid 
synthesis, both basally and through induction by calcium ionophore.  C1P levels appear to be 
partially rescued via addition of serum to the culture medium, which mimics the possible 
compensation of the CERK-/- mice. This compensation of the CERK-/- mice was also 
demonstrated via the AHR study in comparison to acute downregulation.   In the future we may 
explore the use of microarrays or gene chips to determine which additional genes are 
unregulated in the CERK-/- mice that may contribute to how this mouse model compensated for 
the loss of CERK. As inflammation plays a critical role in many diseases, understanding how 
these interactions modulate eicosanoid levels could lead to potential new drug targets for 
disease therapies.  These new treatments could be vast improvements over current therapies 
which shunt eicosanoid production from one set of enzymes to another, creating additional 
health issues as a result of treatment.   
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CHAPTER 4 
CHARACTERIZATION OF A MOUSE MODEL WITH A TRIPLE MUTATION TO INHIBIT THE 
CYTOSOLIC PHOSPHOLIPASE A2/CERAMIDE-1-PHOSPHATE INTERACTION 
 
4.1 Introduction 
Inflammation is a critical component of many disease states including anaphylaxis, 
cancer, cardiovascular disease, rheumatoid arthritis, diabetes and asthma [144-153].  
Eicosanoids are well established mediators of inflammation, and the initial rate limiting step in 
the production of eicosanoids is the liberation of arachidonic acid from membrane phospholipids 
by a phospholipase A2 (PLA2).  The major phospholipase involved in this release of AA during 
the inflammatory response is group IVA cytosolic phospholipase A2.  Studies from our laboratory 
demonstrated that the bioactive sphingolipid, ceramide-1-phosphate, binds cPLA2α at a three 
amino acid sequence, which is located in the cationic β-groove of the C2 domain of cPLA2α 
[126].  Our laboratory further demonstrated that this binding of C1P to cPLA2α increases the 
membrane association of the enzyme upon activation by inflammatory agonists.  These studies 
illustrated that C1P is required for the translocation of cPLA2α, release of arachidonic acid, and 
subsequent production of downstream eicosanoids in response to several inflammatory 
agonists [118,126]. 
Previously, a cPLA2α knockout mouse was generated by two laboratories [103,137], and 
multiple inflammatory conditions were evaluated to elucidate in vivo phenotypes attributed to 
cPLA2α [103,137].  One of the conditions examined was ovalbumin-induced anaphylactic 
response [103], and Uozumi and colleagues demonstrated that the cPLA2α knockout mice 
recovered from anaphylaxis quicker than their wild type counterparts.  In regards to C1P in this 
mechanism, Igarashi and co-workers demonstrated that the anabolic enzyme for C1P, ceramide 
kinase, regulates the activation of mast cells, the main mediators of anaphylactic responses.   
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Anaphylaxis is a severe systemic allergic reaction that occurs quickly upon exposure to 
an allergen and requires prompt, effective treatment and subsequent follow up care.  The 
incidence rate of anaphylaxis is on the rise [153].  Specifically, the incidence rate has more than 
doubled – from 21 per 100,000 people in the 1980s to 49.8 per 100,000 people in the 1990s 
[189].  From 1994 to 2005 the New York statewide hospitalization rate for anaphylaxis rose from 
17 per million people to 42 per million people [191].  The fatality rate of anaphylaxis in the US is 
estimated at 500-1000 people per year [192], in the UK is estimated at 0.33 per million people 
per year [193,194], and in Australia is estimated at 0.64 per million per year [195,196].  The 
primary mechanism of anaphylaxis occurs through crosslinking of IgE and aggregation of FcεRI 
on mast cells and basophils [153].  Downstream of the initiating trigger and mechanism, 
preformed mediators (e.g. histamine) are released during degranulation of mast cells as well as 
activation of cPLA2α, and the subsequent release of AA and production of eicosanoids by COX 
and lipoxygenase enzymes [153].  Eicosanoids are bioactive lipids and well known inflammatory 
mediators that are produced as a result of mast cell activation in the anaphylactic response.  
Primarily, cysteinyl leukotrines and prostaglandin D2 (PGD2) are produced in the anaphylactic 
response [211], and published findings from both the cPLA2α knockout and 5-lipoxygenase (5-
LO) knockout mice have illustrated that eicosanoid pathways are involved in anaphylaxis.   
As the activation of cPLA2α and downstream production of eicosanoids is vital in the 
anaphylaxis process, further characterization of the cPLA2α/C1P interaction in vivo could lead to 
a greater understanding of the systemic effects of this interaction.  In this respect, our laboratory 
has generated a new mouse model: a cPLA2α knock-in mouse with a triple mutation of R57A, 
K58A, R59A to inhibit the C1P/cPLA2α interaction.  Additionally, we have created a cPLA2α 
knockout mouse line.  Therefore, we have, in-house, two perfect controls for establishing 
phenotypes which are specific to the cPLA2α knock-in mouse – a cPLA2α knockout mouse and 
a cPLA2α wild type mouse.   
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Based on our previous studies, we hypothesized that that the C1P/cPLA2α interaction 
was required for all cPLA2α functionality in vivo.  In this study we show that the cPLA2α knockin 
mice do not have a breeding issue, but may potentially exhibit a moderate resistance phenotype 
for passive systemic anaphylaxis at an increased age.  Additionally, we are in the process of 
developing a high-throughput fluorescent assay to analyze potential C1P/cPLA2α interaction 
inhibitors.  As our new mouse model did not exhibit all of the same phenotypes as the cPLA2α 
knockout mouse for the phenotypes we examined, we had to alter our hypothesis involving the 
C1P/cPLA2α interaction and its role in vivo.  Rather than the C1P/cPLA2α interaction being 
critical to all functions of cPLA2α to the C1P/cPLA2α interaction being important in specific 
functions of cPLA2α, it must be critical to specific functions of cPLA2α.  We will continue our 
evaluation of the cPLA2α knockin mouse and will determine if any of the phenotypes observed 
with the cPLA2α knockout mouse are observed in our new cPLA2α knockin mouse model.   
 
4.2 Materials and Methods 
4.2.1 Cell culture 
Primary mouse embryonic fibroblasts (MEFs) were isolated from 13 or 14 days pregnant 
mice as previously described [238] and maintained for three or less passages in high glucose 
Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 20% fetal bovine serum 
(Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at standard incubation conditions. For 
immortalized MEFs, the cells were passaged every 3 days, and after 20 serial passages of the 
primary MEFs, immortalized MEFs were obtained.   Immortalized MEFs were grown in high 
glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum (Invitrogen) and 2% penicillin/streptomycin (BioWhittaker) at 5% CO2 at 37°C and 
passaged every 2 days.    
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4.2.2 Generation of mice 
 To generate PLA2-AAA (lox-stop-lox, LSL) mice, a PLA2-AAA (LSL) targeting vector 
was constructed.  Contiguous PLA2 genomic regions were generated by high-fidelity PCR from 
129/SvEv embryonic stem (ES) cell DNA and sequentially cloned into the PTKV/LSL targeting 
vector, which contains a puromycin phosphotransferase (puro) cassette for positive selection of 
homologous recombinants with puromycin, a thymidine kinase (tk) cassette for negative 
selection of non-homologous recombinants with gangcyclovir, and a lox-stop-lox (LSL) cassette 
for regulating expression of the PLA2-AAA allele.  The final PLA2-AAA (LSL) targeting vector 
possesses a 5' homology arm containing part of PLA2 intron 3, and a 3' homology arm 
containing PLA2 exons 4 and 5.  Codons 57-59 in exon 4 were converted from 5'-
AGG/AAG/CGA-3' (RKR) to 5'-GCG/GCG/GCA-3' (AAA) by PCR-based mutagenesis. 
The PLA2-AAA (LSL) targeting vector was linearized with Acl I and electroporated into 
129/SvEv ES cells.  ES cell clones resistant to both puromycin and gangcyclovir were screened 
for homologous recombination by Southern blot analysis using both 5'-flanking genomic and 
LSL cassette probes, and by long-range PCR using LSL cassette primers in combination with 
flanking genomic primers.  The retention of the RKR to AAA triple substitution in homologous 
recombinants was verified by Hha I digestion of a 3' arm PCR product.  Two ES cell clones 
possessing the PLA2-AAA (LSL) allele were injected into C57BL/6 blastocysts, which were then 
implanted into pseudopregnant CD-1 recipients.  Chimeric male offspring were bred to C57BL/6 
females, and agouti offspring screened for the PLA2-AAA (LSL) allele with a 3-primer PCR 
protocol using a common PLA2 intron 3 sense primer (5'-TGAGGGTCGTGCTGTAGAGTTAG-
3'), in combination with an intron 3 anti-sense primer specific for the wild-type allele (5'-
TGCCAGATGTGAACTTACTTCCAG-3') and an LSL cassette primer specific for the PLA2-AAA 
(LSL) allele (5'-CCAGCTCATTCCTCCCACTCATG-3').  PCR products for the wild-type PLA2 
and PLA2-AAA (LSL) alleles were 247 bp and 400 bp, respectively. 
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 To generate mice expressing the AAA knock-in allele, the original chimera was bred to 
an Ella-cre transgenic female, which expresses Cre in the germline, to delete the LSL cassette 
from the targeted allele.  Mice from this mating were screened by PCR for the PLA2-AAA allele 
using only the two PLA2 intron 3 primers from the 3-primer protocol.  PCR products for the wild-
type PLA2 and PLA2-AAA alleles were 247 bp and 376 bp, respectively.   
 After these initial generations of both the cPLA2α knockout and the cPLA2α knockin 
mice were obtained, the mice were bred into the C57BL/6 background.  For all experiments, 
mice were generation, age, sex, and litter matched.   
We would like to thank Dr. Shirley Taylor from the VCU Massey Cancer Center 
Biological Macromolecule Shared Resource for design and creation of the targeting vector 
utilized to generate these mice.  We would also like to thank Dr. Jolene Windle from the VCU 
Massey Cancer Center Transgenic/Knock-out Mouse Facility for her work and expertise in 
developing the cPLA2α knockin and cPLA2α knockout mice. 
All animal studies were approved by the Institutional Animal Care and Use Committee at 
Virginia Commonwealth University, and were conducted in accordance with the Animal Welfare 
Act, the PHS Policy on Humane Care and Use of Laboratory Animals, and the U.S. Government 
Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and 
Training. 
 
4.2.3 Breeding studies  
 Multiple breeding pairs (one male and one female) of each genotype (cPLA2α knockin, 
cPLA2α knockout, and cPLA2α wild type) were paired to examine the litter size.  This setup was 
performed on multiple occasions.  Mice were monitored every 2-3 days post pairing to ensure 
good health. After the mother had given birth, the number of pups per litter were counted (on 
day of birth) to assess the litter size. 
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4.2.4 Passive systemic anaphylaxis 
All injections were performed i.p. in a final volume of 100 µl per injection.  Mice were 
injected with 50 µg DNP-specific mouse IgE (provided by D. Conrad, VCU, Richmond, VA) and, 
12-18 hours later, with 100 µg DNPalbumin (Sigma-Aldrich) in PBS. Immediately before the Ag 
challenge, body temperature of each animal was measured using a rectal microprobe 
(Physitemp Instruments) and monitored up to 90 min after Ag challenge. Mice were then 
euthanized and blood was collected by cardiac puncture for plasma analysis.   
 
4.2.5 Recombinant expression of cPLA2α 
Recombinant human cPLA2α with a 6XHis tag was expressed in Sf9 cells using a 
baculovirus expression system and purified using a modified protocol as previously described 
[123,265].  Briefly, Sf9 cells were grown and infected with high-titer recombinant baculovirus for 
72 h after infection. The cells were then harvested and resuspended in 10 mL of extraction 
buffer (50 mM Tris, pH 8.0, 200 mM KCl, 5 mM imidazole, 10 mg/mL leupeptin, and 1 mM 
PMSF) using a hand-held homogenizer. The cells were broken by 20 strokes with a Dounce 
homogenizer. The cell lysate was clarified by centrifugation at 100,000 g for 45 min at 4°C. The 
cleared lysate was batch-bound to 10 mL of nickelnitrilotriacetic acid agarose for 30 min in a 
column. Once this solution passed through, the column was washed with 15 mL of buffer 1 (50 
mM Tris, pH 7.2, 0.2 M KCl, 10 mM imidazole, and 10% glycerol). Subsequently, the column 
was washed with 15 mL of buffer 2 (50 mM Tris, pH 8.0, 0.1 M KCl, 15 mM imidazole, and 10% 
glycerol). Third, the column was washed with 15 mL of buffer 3 (50 mM Tris, pH 8.0, 0.1 M KCl, 
20 mM imidazole, and 10% glycerol). The protein was eluted in 1 mL fractions using 10 mL of 
buffer 4 (50 mM Tris, pH 8.0, 0.1 M KCl, 250 mM imidazole, and 10% glycerol). The enzyme 
fractions were monitored using SDS-PAGE, and fractions containing significant amounts of 
cPLA2α were pooled, concentrated, and desalted in an Ultracel YM-50 centrifugal filter device. 
139 
 
 
 
Protein concentration was determined by the bicinchoninic acid method, and aliquots of 0.1 
mg/mL were made using storage buffer (50mMTris, pH 7.4, 0.1 M KCl, and 30% glycerol).  
Activity of recombinant protein was assessed using the EnzChek PLA2 kit from Invitrogen. 
 
4.2.6 Mixed micelle assay for cPLA2α 
cPLA2α activity was measured in a PC mixed-micelle assay in a standard buffer 
composed of 80 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM free Ca2+, and 1 mM DTT. The 
assay also contained 0.3 mM PAPC with phospholipase A2 substrate (Red/Green BODIPY PC-
A2) (Invitrogen), 2 mM Triton X-100, 26% glycerol, and 500 ng of purified cPLA2 protein in a 
total volume of 200 µL. To prepare the substrate, an appropriate volume of PAPC in chloroform, 
the BODIPY substrate, and C8 C1P were evaporated under nitrogen. Triton X-100 was added 
to the dried lipid to give 4-fold concentrated substrate solution (1.2 mM PAPC). The solution 
was probe-sonicated on ice (1 min on, 1 min off for 3 min). The reaction was initiated by adding 
500 ng of the enzyme.  The amount of substrate cleaved was determined by assessing the 
fluorescent emission at 515 nm. All assays were conducted for 45 min at 37°C. Triton X-100 
micelles provide an inert surface for cPLA2 containing an average of 140 molecules per micelle 
(molecular weight = 95,000). Therefore, 1 mol% of the lipid is equivalent to 1.4 molecules per 
micelle and each micelle interacts with 2 molecules of enzyme in a ratio of 1:2.  
 
4.2.7 Ethical considerations 
Breeding pairs of the cPLA2α knockin mice (C57BL/6 background) and cPLA2α knockout 
mice (C57BL/6 background) were bred kept in the animal care facility at VCU. The mouse 
studies were undertaken under the supervision and approval of the VCU IACUC (Protocol# 
AM10089) following standards set by the Federal and State government. The animal assurance 
number for VCU is A2381-01.  
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4.3 Results 
4.3.1 Generation of cPLA2α knockin and knockout mice 
Previously, our laboratory demonstrated that cPLA2α requires the association of C1P for 
the translocation to intracellular membranes, release of AA, and subsequent prostaglandin 
synthesis [118].  This interaction was further characterized and the specific C1P interaction site 
was identified in a cationic patch on the β-groove of cPLA2α (Arg57,Lys58,Arg59) which lies in the 
C2/CaLB domain [126].  These findings lead to the development of the hypothesis that loss of 
the C1P/ cPLA2α interaction would lead to a loss of all cPLA2α function in vivo.  With this 
hypothesis, the Chalfant laboratory created a knockin mouse with a triple mutation of R57A, 
K58A, R59A to inhibit the C1P/cPLA2α interaction.  During this undertaking, we decided that 
creation of our own cPLA2α knockout mouse would also be beneficial.  With having all three 
genotypes of mice, we have built in controls for phenotype assessment of the cPLA2α knockin 
mouse. 
 To create this knockin mouse, we utilized Cre/Lox, or site specific recombination 
technology. A targeting vector with the mutation was created (Figure 4-1, cPLA2α) and was then 
introduced into embryonic stem cells.  Embryonic stem cell clones that were resistant to 
puromycin were screened for homologous recombination via Southern blot analysis and long-
range PCR.  ES cell clones possessing the LSL allele were injected into C57BL/6 blastocysts 
and implanted into pseudopregnant CD-1 mice.  Chimeric male offspring mice were bred to 
C57BL/6 females, and agouti offspring were screened for the LSL allele.  These mice containing 
the LSL allele became the cPLA2α KO mouse line and were backcrossed into the C57BL/6 
background.  To generate the cPLA2α KI mice, the chimeric male offspring were bred to an Ella-
cre transgenic female (expresses Cre in the germline).  Mice from this mating were screened via 
PCR for removal of the LSL allele and presence of the KI allele.  Mice containing the KI allele 
were backcrossed into the C57BL/6 background and became the cPLA2α KI mouse line. 
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Figure 4-1.  Design of the cPLA2α knockin mouse.  Targeting construct designed to introduce 
three mutations (***) into exon 4 of the endogenous cPLA2α locus.  A lox-stop-lox targeting 
vector was constructed to regulate the expression of the cPLA2α allele.  If the lox-stop-lox 
cassette is included during recombination, expression of the cPLA2α gene is halted, creating a 
cPLA2α knockout mouse.  If the lox-stop-lox cassette is removed during recombination, the 
cPLA2α gene with the mutations (R57A, K58A, R59A) is expressed, creating a cPLA2α knockin 
mouse.  See the materials and methods section for a detailed description of the creation of the 
mouse lines. 
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4.3.2 cPLA2α knockin mice do not show the breeding deficiency observed with the 
cPLA2α knockout mice 
 Initially we hypothesized that the C1P/cPLA2α interaction was required for all cPLA2α 
functionality in vivo.  Based on this hypothesis, we began investigating various phenotypes that 
were observed in the cPLA2α knockout mouse.  The first phenotype examined was reduced 
fertility.  This phenotype was found in the cPLA2α knockout mice by Uozumi and colleagues 
[103] and by Bonventre et al [137].  Both groups found that cPLA2α knockout litters produced a 
smaller number of pups and the pups typically did not survive [103,137].  We were able to 
reproduce this phenotype with our cPLA2α knockout mice (Figure 4-2).  Surprisingly, our 
preliminary data do not indicate any breeding issues for the cPLA2α knockin mice, as these 
mice produced litters with approximately the same average number of pups per litter as the 
cPLA2α wild type mice (Figure 4-2). 
We will repeat these preliminary studies as we now have mice that are seven 
generations into the C57BL/6 background.  Additional breeding studies of heterozygous mice as 
well as male cPLA2α KO mice paired with female WT mice and male cPLA2α KI mice paired 
with female WT mice will be performed to determine if there is any loss of functionality that is 
specifically related to the males rather than the female mice.  This unexpected result indicates 
the C1P/cPLA2α interaction is not required for all cPLA2α functionality in vivo.  Thus, we were 
presented with two possibilities – 1) the C1P/cPLA2α interaction is not required for the 
functionality of cPLA2α in vivo, which would contradict our previous in vitro studies, or 2) the 
C1P/cPLA2α interaction is required for specific functionality of cPLA2α in vivo. 
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Figure 4-2. cPLA2α knockin mice do not show the same breeding deficiencies as cPLA2α 
knockout mice.  Wild type, cPLA2α knockin, and cPLA2α knockout mice were paired for 
breeding (1 male to 1 female).  The litter size was evaluated on day of birth.   
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4.3.3 Passive systemic anaphylaxis 
 In order to assess if the C1P/cPLA2α interaction is important for any cPLA2α functionality 
in vivo, we began investigating additional phenotypes.  The cPLA2α knockout mouse has been 
studied in depth, and a published report shows that cPLA2α knockout mice demonstrate 
resistance to anaphylactic shock [103].  Igarashi and co-workers also demonstrated that CERK 
regulates the activation of mast cells [266-268], and eicosanoid production is involved in the 
anaphylactic response.  Based upon these findings and the expertise in PSA at VCU [270-272], 
we decided to examine this phenotype in regards to our cPLA2α knockin mice.  We then 
performed an abbreviated pilot study to examine the phenotype of the cPLA2α knockin mice 
when passive systemic anaphylaxis is induced.  The drop in body temperature observed with 
the cPLA2α WT mice is indicative of anaphylaxis (Figure 4-3).  The cPLA2α KO mice had no 
change in body temperature (Figure 4-3), which was expected based upon the study by Uozumi 
and colleagues [103].  Interestingly, a moderate resistance phenotype with regards to 
anaphylactic shock was observed for the cPLA2α KI mice, as the mice had a delay in the 
decrease in body temperature and the decrease was not as severe as that observed with the 
cPLA2α WT mice (Figure 4-3).  These data suggest that the cPLA2α /C1P interaction is involved 
in the anaphylaxis response, and thus the cPLA2α/C1P interaction must be involved in specific 
functions for cPLA2α.   
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Figure 4-3. cPLA2α knockin mice show a resistance phenotype to passive systemic 
anaphylaxis.  Mice were i.p. injected with antigen-specific IgE (50 µg in 100 µL PBS).  After 12-
18 hours, mice were i.p. injected with 100 µg dinitrophenol (DNP) coupled to human serum 
albumin (HSA) in 100 µL PBS per mouse.  Core body temperature was monitored and recorded 
via a digital rectal thermometer prior to challenge injection, and every ten minutes for a half hour 
post injection. 
 
 
  
149 
 
 
 
After this abbreviated study, we assessed our plans to move forward with additional 
testing in regards to assessing the phenotype of the cPLA2α knockin mice and passive systemic 
anaphylaxis.  During our research into anaphylaxis, we found that the severity of anaphylaxis is 
increased in elderly patients.  For example, in a postmortem analysis by Greenberger et al, the 
authors found that elderly patients, particularly those with comorbid conditions such as 
cardiovascular disease, comprised a significant number of the fatalities due to anaphylaxis 
[198].  Results from additional studies performed in Australia indicate that older age is 
associated with a more severe grade of anaphylaxis [196,199].  A report performed in Central 
Europe corroborated these findings demonstrating an increasing risk of developing circulatory 
symptoms in addition to cutaneous symptoms with an increase in age [200].  Interestingly, a 
report by Nguyen et al provided a possible link as to the cause of this increase in incidence with 
age.  Utilizing a mouse model, the authors demonstrated that IgE/Ag-mediated mast cell 
degranulation and edema formation increased with the age of the mice as well as evidence that 
PGE2, the bioactive lipid, becomes a mast cell stimulator with increasing age [201].   
Based upon these studies, we hypothesized that as our mice age, the wild type mice will 
become more sensitive to passive systemic anaphylaxis whereas the cPLA2α knockin mice will 
remain resistant.  From this hypothesis, we set out to test mice in two age groups: 1) 6-8 weeks 
of age and 2) 14-16 weeks of age.  We first tested the younger mice, those that were 6-8 weeks 
of age.  Interestingly, all mice, regardless of genotype, were resistant to PSA at this age (Figure 
4-4). 
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Figure 4-4. Younger mice show a resistance phenotype to passive systemic anaphylaxis.  
Mice were i.p. injected with antigen-specific IgE (50 µg in 100 µL PBS).  After 12-18 hours, mice 
were i.p. injected with 100 µg dinitrophenol (DNP) coupled to human serum albumin (HSA) in 
100 µL PBS per mouse.  Core body temperature was monitored and recorded via a digital rectal 
thermometer prior to challenge injection, and every ten minutes for a half hour post injection. 
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After it was observed that young mice, regardless of genotype, do not undergo 
anaphylaxis, we moved on to evaluation of the older group of mice, 14-16 weeks of age.  We 
tested multiple mice from each genotype, and, with these older mice, we were able to induce 
passive systemic anaphylaxis (Figure 4-5).  Individually, responses to PSA varied with each 
mouse within each genotype (Figure 4-5, Panel A).  When responses were averaged, both wild 
type and knockin mice appeared to undergo anaphylaxis, while the knockout mice presented a 
delayed anaphylaxis phenotype (Figure 4-5, Panel B).   
 Additional mice at this age must still undergo analysis, in order to determine statistical 
significance among genotypes.  Also, as we did not observe the same phenotype as the pilot 
study, we will analyze mice that are older still, age 22-26 weeks, to determine if the mice must 
be older in order to replicate the first observed phenotype. 
 
  
153 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Older mice show a susceptible phenotype to passive systemic anaphylaxis.  
Mice were i.p. injected with antigen-specific IgE (50 µg in 100 µL PBS).  After 12-18 hours, mice 
were i.p. injected with 100 µg dinitrophenol (DNP) coupled to human serum albumin (HSA) in 
100 µL PBS per mouse.  Core body temperature was monitored and recorded via a digital rectal 
thermometer prior to challenge injection, and every ten minutes for a half hour post injection. 
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4.3.4 Development of the cPLA2α fluorescent mixed micelle assay 
 We also wanted to adapt our previously reported mixed micelle assay [132] to use a 
fluorescent substrate and a 96-well plate format.  The goal is to be able to detect a difference in 
cPLA2α activity based on the presence or absence of C1P in the system.  With this assay, when 
C1P is present, the activity of cPLA2α is typically increased approximately 8-fold [132].  For the 
development of this assay, we utilized in-house made cPLA2α (as described in the Materials 
and Methods section) and a fluorescent substrate purchased from Invitrogen. 
 The first step necessary to the development of our assay was to determine if our 
recombinant cPLA2α was active.  To assess the activity of our cPLA2α, we utilized the EnzChek 
PLA2 kit from Invitrogen.  As see in Figure 4-6, our cPLA2α is indeed active. 
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Figure 4-6.  In house manufactured recombinant cPLA2α is active.  The recombinant 
cPLA2α produced in-house through a baculovirus system was assayed using the EnzCheck 
PLA2 kit (Invitrogen) as described in the Materials and Methods section. 
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 The second step was simply substitution of the radiolabled PAPC in the previously 
reported assay [132] with the same amount of fluorescent substrate as is used in the Invitrogen 
kit.  However, this did not produce a very linear curve and also produced a high background 
signal (Figure 4-7). 
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Figure 4-7.  First adaption of mixed micelle assay produced high background and no 
linear curve.  Mixed micelle assay was performed according to the procedure in Materials and 
Methods section.  Wide variation between repeat curves produced no linear curve.  N=4. 
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We then examined whether heat was the cause of the high background signal as the 
previously developed method required being run at 37°C whereas the PLA2 assay by Invitrogen 
required being run at room temperature.  We repeated this assay with an adjustment of running 
the assay at room temperature.  This did not produce any improved results; and therefore 
determined that it must be a component of the assay which is causing the high background 
readings.  All assay components were tested individually with the substrate and results were 
analyzed.  The Triton X-100 proved to be the assay component responsible for the high 
background (Figure 4-8). 
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Figure 4-8.  Analysis of assay components.  Each component of the mixed micelle assay 
was tested with the fluorescent substrate and analyzed for fluorescence.  Triton X-100 was 
found to be the buffer component responsible for the high background. 
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 A literature search was then conducted to determine if there was a possible way to 
correct for this high background issue.  A 2007 publication from Wichmann et al. [269] 
discussed the issue of fluorescent substrates in mixed micelle formats while utilizing Triton X-
100.  In this publication, the authors stated that using a much reduced concentration of the 
fluorescent substrate would aid in avoiding intermolecular energy transfer which could cause a 
high background signal and/or false positives.  Based upon this report, we adjusted the 
concentration of the fluorescent substrate in our assay, and were pleased to see a linear curve 
with a reduced background when the assay was performed (Figure 4-9). 
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Figure 4-9.  Reducing the concentration of fluorescent substrate reduced background 
and produced a linear curve. 
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Now that the assay appeared to be functional, we next wanted to assess the results of 
introducing C1P to the system.  4 mol% C1P was added to the micelles, and the assay was 
performed.  Unfortunately, an increase in activity when C1P was in the system was not 
observed, and the standard curves were not linear (Figure 4-10).  It is likely that despite the 
reduction in the concentration of the fluorescent substrate, the Triton X-100 is still causing 
enough intermolecular energy transfer to block the increase in activity when C1P is added to the 
system.  Based upon these results and the observation that the Invitrogen assay is vesicle-
based, the next step for this assay development is to adapt our mixed-vesicle assay [132] for 
use with the fluorescent substrate as this assay does not utilize Triton X-100. 
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Figure 4-10.  No difference in activity was seen with the addition of C1P to the mixed 
micelle assay.  (A) Standard curve of cPLA2α assayed without C1P in the micelle.  (B) 
Standard curve of cPLA2α assayed with C1P in the micelle.  No difference was observed with or 
without C1P, and curves were not linear. 
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4.4 Discussion 
  Our laboratory has generated a new mouse model: a cPLA2α knock-in mouse with a 
triple mutation of R57A, K58A, R59A to inhibit the C1P/cPLA2α interaction.  In our in vitro studies, 
this mutant cPLA2α has been shown to not bind C1P, and the mutation does not affect the 
structure of cPLA2α [126].  The result of this non-binding is that the mutant enzyme does not 
translocate in response to inflammatory agonists, and subsequently prostaglandin synthesis 
(PGE2) is inhibited [118].  In our new mouse model, the mutant cPLA2α is produced and is 
enzymatically active.  Based on our previous studies, we hypothesized that that the 
C1P/cPLA2α interaction was required for all cPLA2α functionality in vivo.  We have begun 
characterization of this new mouse model and have utilized both wild type cPLA2α and cPLA2α 
knockout mice as controls.  In this study we show that the cPLA2α knockin mice do not have a 
breeding issue, but may potentially exhibit a moderate resistance phenotype for passive 
systemic anaphylaxis at an increased age.  Additionally, we are in the process of developing a 
high-throughput fluorescent assay to analyze potential C1P/cPLA2α interaction inhibitors. 
 The first phenotype that was observed in the cPLA2α knockout mouse, reduced fertility 
(e.g. cPLA2α knockout mice produce smaller litters) [137], was the first phenotype examined for 
our cPLA2α knockin mice.  Unexpectedly, our preliminary data indicate a lack of this phenotype 
in the cPLA2α KI mice (Figure 4-2).  This result indicates that our initial hypothesis that the 
C1P/cPLA2α interaction was required for all cPLA2α functionality in vivo was incorrect.  After this 
observation, we had to reevaluate our hypothesis.  There were two possibilities in regards to the 
importance of the C1P/cPLA2α interaction – either the C1P/cPLA2α interaction is not important 
at all for the function of cPLA2α, or the C1P/cPLA2α interaction is only important for very specific 
functions of cPLA2α. 
The best way to determine which hypothesis is correct was to continue the evaluation of 
additional phenotypes to determine which cPLA2α knockout phenotypes would replicate in our 
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cPLA2α knockin mouse model.  The cPLA2α knockout mouse has been studied in depth, and a 
published report shows that cPLA2α knockout mice demonstrate resistance to anaphylactic 
shock [137].  Igarashi and co-workers also demonstrated that CERK regulates the activation of 
mast cells [266-268], and eicosanoid production is involved in the anaphylactic response.  
Based upon these findings, we performed an abbreviated pilot study to examine the phenotype 
of the cPLA2α knockin mice when passive systemic anaphylaxis is induced.  Indeed, a moderate 
resistance phenotype with regards to anaphylactic shock was observed (Figure 4-3), as the 
cPLA2α knockin mice appeared to undergo a less severe body temperature drop and also 
appeared to begin recovery more quickly than the cPLA2α wild type mice.  We were able to 
replicate the resistance phenotype previously published for the cPLA2α knockout mice.  These 
data suggested that the cPLA2α/C1P interaction is involved in the anaphylaxis response, and 
thus we wanted to continue our exploration into this phenotype with additional studies.   
Through our research into anaphylaxis, we found that the severity of anaphylaxis is 
increased in elderly patients [198-199,196,200], so we wanted to explore the role of age in 
anaphylaxis in our mouse models.  We tested mice that are 6-8 weeks of age and mice that are 
14-16 weeks of age for passive systemic anaphylaxis.  All genotypes of the young mice showed 
resistance to PSA (Figure 4-4), while at 14-16 weeks mice of all genotypes appeared to 
undergo anaphylaxis (Figure 4-5).  These data revealed to us that younger mice are not 
susceptible to PSA and that older mice are a better candidate for this model.  Based upon these 
data and discussions with the Ryan lab, we next want to explore PSA with older mice, aged 
approximately 22-26 weeks, to determine if the severity of anaphylaxis increases in these 
elderly mice.  It is possible that the C1P/cPLA2α interaction does not play a role in aging and 
anaphylaxis, rather the role of the interaction is involved in the general mechanism of passive 
systemic anaphylaxis.  Once we have determined the exact phenotype of the cPLA2α knockin 
mouse, we will further explore the roles of the mast cells and the endothelial cells in this 
phenotype, as either could be the major player for the phenotype observed.   
171 
 
 
 
 The development of the mixed micelle assay was to have this tool readily available to 
screen libraries of compounds in the presence and absence of C1P.   Based on our results thus 
far with the development of this assay, we hope that adaption of the mixed vesicle assay for use 
with the fluorescent substrate will present a viable alternative to the mixed micelle adaptation.  
However, if this does not resolve our issues, we will explore other options for a fluorescent 
substrate that may be more suitable to these assays.  As we believe that the cPLA2α/C1P 
interaction will prove to be an excellent drug target in the future, this tool will be critical to the 
identification of potential inhibitory compounds.  A positive signature for an inhibitor of the 
cPLA2α/C1P interaction would be a compound showing no basal effect on cPLA2α activity while 
blocking the 10- to 15-fold induction of enzyme activity induced by C1P. Any 1st generation 
compounds identified would lead to the rapid production of 2nd and 3rd generation compounds 
for pre-clinical experiments and initial clinical trials 
 Interestingly, our new mouse model does not exhibit all of the same phenotypes as the 
cPLA2α knockout mouse.  This leads us to alter our hypothesis involving the C1P/cPLA2α 
interaction and its role in vivo, and based on our current results we believe that the C1P/cPLA2α 
interaction is important for very specific functions of cPLA2α.  Our study regarding the 
moderately resistant phenotype observed for PSA with the cPLA2α knockin mice will continue 
and we will elucidate the specific phenotype for this mouse.  We will continue our evaluation of 
the cPLA2α knockin mouse and we will explore other phenotypes that have been observed with 
the cPLA2α knockout mouse.  We will first focus on additional inflammatory models, as cPLA2α 
is critical in the inflammatory process. Evaluation of additional phenotypes will aid in 
development of a hypothesis regarding in which functions the C1P/cPLA2α interaction is critical.  
We will also further investigate the potential role the C1P/cPLA2α interaction plays in the 
activation of this enzyme, as this interaction is not crucial for all activities of cPLA2α. 
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